simvastatin has been researched along with Hyperlipemia in 411 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (1.46) | 18.7374 |
| 1990's | 85 (20.68) | 18.2507 |
| 2000's | 193 (46.96) | 29.6817 |
| 2010's | 110 (26.76) | 24.3611 |
| 2020's | 17 (4.14) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, A; Alvaro, R; Berger, JP; Cai, TQ; Dropinski, JF; Heck, JV; Hernandez, M; Macnaul, KL; Meinke, PT; Moller, DE; Sahoo, SP; Santini, C; Shi, GQ; Wright, SD; Zhang, Y; Zhou, G | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Caspers, N; Choi, C; Dillon, L; Hanselman, JC; Harris, MS; Larsen, SD; Lin, Z; Lu, G; Pavlovsky, A; Pfefferkorn, JA; Robertson, A; Sekerke, C; Song, Y; Trivedi, BK | 1 |
| Askew, V; Auerbach, B; Bainbridge, G; Bratton, LD; Caspers, N; Chen, H; Cheng, XM; Choi, C; Dillon, L; Eberstadt, M; Erasga, N; Hanselman, JC; Harris, MS; Larsen, SD; Lee, C; Lin, Z; Lu, G; Mertz, T; Miller, SR; Olsen, K; Pavlovsky, A; Pfefferkorn, JA; Poel, TJ; Robertson, A; Sekerke, C; Song, Y; Sorenson, RJ; Sun, KL; Trivedi, BK; Unangst, PC | 1 |
| Katselou, MG; Kourounakis, AP; Matralis, AN; Nikitakis, A | 1 |
| Kourounakis, AP; Ladopoulou, E; Matralis, AN | 1 |
| Kourounakis, AP; Ladopoulou, EM; Matralis, AN; Nikitakis, A | 1 |
| Chernus, N; Gorenkov, R; Savina, T; Sivkov, A; Sivkov, S; Sivkova, S | 1 |
| Adamson, SS; Biddinger, SB; Bullock, K; Chahar, S; Clish, CB; Crooke, RM; de Ferranti, SD; Gearing, ME; Graham, MJ; Hagey, LR; Kidambi, S; Krawczyk, J; Levenson, AE; Ling, AV; Miao, J; Semova, I; Shin, DJ; Vicent, D; Williams, KA | 1 |
| Ahn, YM; Bang, OS; Jung, J; Kim, HL; Lee, SM; Park, SH; Seo, CS | 1 |
| Dang, L; Gao, F; Qu, Q; Wang, J; Wei, S | 1 |
| Hu, YX; Jing, Q; Li, FF; Liang, C; Liang, YL; Qin, YW; You, HM; Zhao, XX; Zhu, RF | 1 |
| Koumaravelou, K; Sarathchandiran, I; Selvasudha, N | 1 |
| Arancón-Monge, JM; Campos-Díaz, L; de Castro-Cuenca, A; Del Cura-González, I; Rodríguez Barrientos, R; Serrano-Vázquez, Á | 1 |
| DʼAcunto, K; Sismour, B | 1 |
| Chaâbane, M; El Feki, A; Koubaa-Ghorbel, F; Makni-Ayadi, F; Turki, M | 1 |
| Han, L; Li, H; Liu, R; Mushtaq, N; Shi, Y; Ullah, S; Wu, R; Xu, J; Yuan, L; Zhang, J; Zhang, S | 1 |
| Alem, C; Bouhlali, EDT; Bourkhis, B; Filali-Zegzouti, Y; Harnafi, H; Hmidani, A; Khouya, T | 1 |
| Cai, Q; Fan, J; Jiang, S; Qu, X; Weinstock, J; Zhang, D | 1 |
| An, X; Chen, S; Li, H; Liu, C; Rabearivony, A; Zhang, W | 1 |
| Cai, Q; Fan, J; Hu, S; Jiang, S; Venners, SA; Zhang, D | 1 |
| Bai, WW; Dong, B; Fu, CN; Guo, T; Li, P; Liu, C; Song, JW; Song, ZP; Wang, QW; Wang, SX | 1 |
| Abdelsalam, RM; Abo-Zalam, HB; El-Denshary, ES; Hamzawy, MA; Khalil, IA; Khattab, MM | 1 |
| Florean, EOPT; Guedes, MIF; Holanda, MO; Lima, CLS; Lira, SM; Marques, MMM; Mendes, FNP; Moura, LFWG; Oriá, RB; Paim, RTT; Rodrigues, PAS; Silva, BBD; Silva, JYGD; Vieira, IGP | 1 |
| Chmiel, K; Jurkiewicz, K; Knapik-Kowalczuk, J; Kramarczyk, D; Paluch, M | 1 |
| Chang, X; Chen, Q; Dai, G; Jiang, S; Li, D; Liu, M; Ma, M; Wang, Z; Yue, Z; Zhang, G; Zhang, Q; Zhong, H; Zhou, J; Zou, Y | 1 |
| Duan, F; Guo, Z; Liu, Y; Xian, Z; Xiao, H; Xu, W | 1 |
| Cerda, Á; Hirata, MH; Hirata, RDC; Salazar, LA; Zambrano, T | 1 |
| Abdel-Rahman, S; Gaedigk, A; Gaedigk, R; Kauffman, R; Leeder, JS; Raghuveer, G; Van Haandel, L; Wagner, JB | 1 |
| Cai, Y; Hu, M; Hu, Z; Jia, C; Liu, N; Yang, G; Zhang, M | 1 |
| Gao, L; Lin, Z; Liu, X; Liu, Y; Wan, L; Wang, X; Zhang, L | 1 |
| Cai, M; Kalavagunta, PK; Liu, Q; Lv, W; Pan, Q; Qin, G; Shang, J; Wang, T; Wu, H; Xia, Z; Zhou, L | 1 |
| Cheng, J; Gong, C; Hsu, YH; Hu, S; Jiang, S; Li, Y; Pan, F; Venners, SA; Weinstock, J; Wu, S; Wu, X; Xu, X; Zha, X | 1 |
| Cheung, LK; Chow, DS; El-Zailik, A; Sherman, V; Wang, Y | 1 |
| Arbağ, H; Cure, E; Eryilmaz, MA; Özer, AB; Yücel, A; Yücel, H | 1 |
| Almajaan, A; Andrews, GP; Healy, A; Jones, DS; Li, S; Martini, L; Yu, T | 1 |
| Han, SN; Tao, HL; Yang, WH; Yin, JJ; Zhang, LR | 1 |
| Ali, KH; Ansari, MM; Choe, YH; Din, FU; Khan, N; Kim, JK; Kim, KW; Muhammad, I; Qureshi, OS; Rizvi, SZH; Shah, FA; Zeb, A | 1 |
| Bilušić, M; Blažević, N; Bradamante, V; Konjevoda, P; Lovrić, J; Vukšić, A | 1 |
| Feng, R; Ji, ZC; Jin, XY; Li, XM; Yang, FW; Zhang, BL; Zhang, JH; Zhang, LS; Zhang, MY; Zhao, MY | 1 |
| Abdel-Rahman, S; Galetin, A; Leeder, JS; Ogungbenro, K; Wagner, JB | 1 |
| Abdalla, FH; Bernardes, VM; Braun, JBS; Casali, EA; Castilhos, LG; da Cruz, IBM; de Andrade, CM; de Oliveira, JS; Leal, DBR; Manzoni, AG; Passos, DF; Ruchel, JB | 1 |
| Balu, S; Montouchet, C; Ruff, L | 1 |
| Cziraky, M; Jacobson, TA; Kuznik, A; Wertz, DA | 1 |
| Chen, Q; Hsu, YH; Jiang, S; Venners, SA; Wang, X; Xing, H; Xu, X; Zhong, G | 1 |
| Jin, R; Le, NA; Neff, DR; Tershakovec, AM; Tomassini, JE; Wilson, PW | 1 |
| Byrnes, JR; Mackman, N; Owens, AP | 1 |
| Berg, RL; Davis, RL; Denny, JC; Feng, Q; Iwuchukwu, OF; Jiang, L; Jiang, M; Krauss, RM; McCarty, CA; Nickerson, DA; Peissig, PL; Roden, DM; Rotter, JI; Waitara, MS; Wei, WQ; Wilke, RA; Xu, H | 1 |
| Gong, X; Tang, M; Wu, SZ | 1 |
| Chaturvedula, A; Lee, H; Sale, ME | 1 |
| Chen, Y; Li, J; Wang, X; Wu, J; Zhang, Z; Zou, J | 1 |
| Snipelisky, D; Stancampiano, F | 1 |
| Bravo, M; Magán-Fernández, A; Marfil-Álvarez, R; Mesa, F; Papay-Ramírez, L; Rizzo, M; Tomás, J | 1 |
| Billot, L; Bompoint, S; Brown, A; Burch, C; Burke, H; Cass, A; Hayman, N; Hillis, GS; Jan, S; Molanus, B; Neal, B; Patel, A; Peiris, D; Rafter, N; Reid, CM; Rodgers, A; Shiel, L; Togni, S; Tonkin, A; Usherwood, T; Webster, R | 1 |
| Hisdal, J; Holme, I; Ikdahl, E; Kvien, TK; Pedersen, TR; Rollefstad, S; Semb, AG | 1 |
| Ashok, P; Poulose, DN; Singh, D; Suresh, B | 1 |
| Djerrou, Z | 1 |
| Li, Q; Lu, F; Wang, H; Wang, Q; Yan, S; Zhu, W; Zhu, X | 1 |
| Cui, GB; Liu, L; Liu, YH; Ma, B; Sun, JJ; Wu, ZM; Xu, QY; Yang, ZD; Yao, D; Zhang, Q | 1 |
| Bishop, I; Campbell, SM; Godman, B; Malmström, RE; Truter, I | 1 |
| Chen, XY; Lan, D; Li, T; Liu, LM; Tian, KL; Wu, Y; Yang, GM; Zhu, Y | 1 |
| Jia, BB; Lv, YD; Mao, GX; Wang, GF; Wang, YZ; Yang, ZX; Yu, H | 1 |
| Majeed, A; Muneera, KE; Naveed, AK | 1 |
| Kukharchuk, VV; Sumarokov, AB | 1 |
| A, R; Bao, N; Borjihan, G; Jin, Z; Qiao, Y; Sun, Z | 1 |
| Aikemu, A; Begaud, B; Berké, B; Iskandar, G; Moore, N; Umar, A; Yiming, W; Zhou, W | 1 |
| Camilli, JA; Fernandes, GJ; Garcia, JA; Nakagaki, WR; Novaes, RD; Soares, EA | 1 |
| Karam, I; Kong, XJ; Li, JY; Li, SH; Liu, XW; Ma, N; Yang, YJ | 1 |
| Parhi, R; Patnaik, S; Suresh, P | 1 |
| Parhi, R; Suresh, P | 1 |
| Banefelt, J; Fox, KM; Gandra, SR; Hallberg, S; Johansson, G; Levin, LÅ; Mesterton, J; Sobocki, P | 1 |
| Foerster, J; Schetz, D; Sein Anand, J | 1 |
| Hsu, YH; Jiang, S; Li, K; Liu, Y; Sun, Y; Venners, SA; Wang, B; Weinstock, J; Xu, X | 1 |
| Ahlquist, P; Bagdat, D; Blegvad, J; Christensen, R; Christensen, TG; Colic, A; Ellingsen, T; Emmertsen, H; Fredberg, U; Giraldi, A; Graugaard, C; Hansen, IM; Hørslev-Petersen, K; Jensen, HS; Løgstrup, BB; Persson, F; Sheetal, E; Svendsen, L; Svensson, AL; Thygesen, T | 1 |
| Correia, LC; Garcia, MM; Góes, PM; Guimarães, AC; Ladeia, AM; Lima, PR; Rodrigues, MG; Silva, Mde L; Silva, PF; Varela, CG | 1 |
| Alfredo, TM; Antunes, KÁ; da Rocha, Pdos S; de Picoli Souza, K; Dos Santos, EL; Espindola, PP; Lopes, RH; Macorini, LF; Pereira, ZV | 1 |
| Alomrani, AH; Badran, MM; Harisa, GI | 1 |
| Chootip, K; Tunsophon, S | 1 |
| Añino Alba, A; Fernandez-Esteban, I; Fernandez-Tabera, JM; Gómez Álvarez, P; Izquierdo-Palomares, JM; Martin-Carrillo, P; Pinar López, Ó; Plana, MN; Saiz, LC | 1 |
| Ferreira, AM; Marques da Silva, P | 1 |
| Barrett, DA; Bruce, KD; de Moor, CH; Eckel, RH; Gershkovich, P; Lee, JB; Sungelo, M; Taha, DA; Zgair, A | 1 |
| Marques, PP; Oliveira, LP; Pimentel, ER; Vieira, CP | 1 |
| Adefegha, SA; Braun, JBS; Castilhos, LG; Coelho, APV; de Andrade, CM; Dornelles, GL; Leal, DBR; Oliveira, JS; Rubin, MA; Ruchel, JB; Signor, C; Trelles, KB | 1 |
| Laurie, SJ | 1 |
| Anzivino, C; Bertolotti, M; Carulli, L; Carulli, N; Corna, F; Del Puppo, M; Gabbi, C; Kienle, MG; Loria, P; Pellegrini, E; Ricchi, M; Zambianchi, L | 1 |
| Hird, MI | 1 |
| Ao, QX; Kuang, Y; Wang, MJ; Wu, XL; Zhang, WJ | 1 |
| Abbott, L; Farah, R; Gopaluni, S; Hutchison, R; Perzova, R; Poiesz, BJ; Shrimpton, A | 1 |
| Zheng, L; Zheng, MW | 1 |
| Sundermeyer, M; Veeraputhiran, M | 1 |
| Farnier, M; Kush, D; Mitchel, YB; Perevozskaya, I; Taggart, WV | 1 |
| Choi, HY; Ham, I; Jung, ED; Lee, J; Yang, G | 1 |
| Kotyla, PJ | 1 |
| Chen, JH; Liao, JK; Lin, LJ; Liu, PY; Liu, YW | 1 |
| Arredondo-García, JL; Bojorquez-Ochoa, A; García-de-la-Puente, S; Gutiérrez-Castrellón, P; Maya, ER; Pérez-Martínez, Mdel P | 1 |
| Couture, P; Hogue, JC; Lamarche, B; Tremblay, AJ | 1 |
| Avorn, J; Brookhart, MA; Brown, TV; Choudhry, NK; Glynn, RJ; Jolda, C; Lee, TH; Schneeweiss, S; Shrank, WH; Snedden, TM; Solomon, DH; Spetman, M | 1 |
| Grenda, R; Ksiazek, J; Lipka, M; Niemirska, A; Syczewska, M; Wierzbicka, A | 1 |
| Wang, XM | 1 |
| Pasternak, RC; Tershakovec, AM; Veltri, EP | 1 |
| Visseren, FL; Westerink, J | 1 |
| Pernow, J; Rydén, L; Settergren, M | 1 |
| Cai, C; Cai, Q; Du, X; Kermany, MH; Yoo, T; Zhang, C; Zhou, B | 1 |
| Bailey, KM; Balmforth, AJ; Barth, JH; Copeland, J; Efthymiou, M; Farrin, AJ; Flather, MD; Hall, AS; Jackson, BM; McCormack, T; Nixon, J; Romaine, SP; Whitehead, A | 1 |
| Goetghebeur, M; Jönsson, B; Lindgren, P; Merikle, E; Wagner, M | 1 |
| Crosslin, DR; Ginsburg, GS; Messer, C; Reed, CR; Salisbury, BA; Shah, SH; Voora, D; Zhai, J | 1 |
| Chuengsamarn, S; Kaufman, L; Rattanamongkoulgul, S; Suwanwalaikorn, S; Wattanasirichaigoon, S | 1 |
| Kasalová, Z; Kvasnicka, J; Mazoch, J; Prázný, M; Skrha, J | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE | 1 |
| Chen, MS; He, ZC; Lu, DF; Wang, W; Wu, J; Xiao, Y | 1 |
| Näntö-Salonen, K; Niinikoski, H; Simell, O; Tanner, LM | 1 |
| Burke, JP; Rublee, DA | 1 |
| Dorlechter, F; Farah, R; Shurtz-Swirski, R | 1 |
| Ballantyne, CM; Davidson, MH; Dicklin, MR; Doyle, RT; Maki, KC | 1 |
| Foody, JM; Liu, LZ; Mendys, PM; Simpson, RJ | 1 |
| Adeneye, AA; Adeyemi, OO; Agbaje, EO | 1 |
| Boaz, M; Gilad, R; Lampl, Y; Lorberboym, M; Sadeh, M; Tikozky, A; Vysberg, I | 1 |
| Hu, XJ; Jia, M; Li, YP; Zhang, LR | 1 |
| Choi, JW; Kim, SH; Lee, H; Lee, SJ; Lim, HE; Park, CG | 1 |
| Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE | 1 |
| Ezekiel, TO; Hylton, AC | 1 |
| Liu, GB; Lu, SZ; Zhao, FH | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Lerdvuthisopon, N; Sritipsukho, P; Teeraaunkul, S; Tharavanij, T; Wongtanakarn, S; Youngsriphithak, P | 1 |
| Boonnak, T; Na Ayutthaya, WD; Suanarunsawat, T; Thirawarapan, S | 1 |
| Inoue, T; Kikuta, T; Sato, T; Suzuki, H; Tsuda, M; Watanabe, Y | 1 |
| Császár, A; Farnier, M; Retterstøl, K; Steinmetz, A | 2 |
| Ahn, BJ; Chae, HS; Choi, J; Doh, K; Han, S; Jun, YK; Kim, J; Lee, YW; Yim, DS | 1 |
| Ijioma, N; Robinson, JG | 1 |
| Jönsson, B; Lindgren, P | 1 |
| Qu, K; Sun, Y; Wang, YH; Zhu, HB | 1 |
| Berggren-Söderlund, M; Luo, G; Mao, S; Nilsson-Ehle, P; Wei, J; Xu, N; Zhang, X | 1 |
| Chong, E; Poh, KK; Shen, L | 1 |
| Furman, A; Lopez, JR; Malmstrom, RA; Meier, JL; Schaefer, S | 1 |
| Charlton-Menys, V; Dissanayake, S; Durrington, PN; France, MW; Kwok, S; Soran, H; Younis, NN | 1 |
| Liu, KS; Wang, HH; Wong, MC | 1 |
| Ahmad, M; Aslam, B; Faisal, I; Javed, I; Khan, MZ; Muhammad, F; Rahman, Z; Shahzadi, A | 1 |
| Aftab, S; Bilal, R; Usman, A; Zakaria, M; Zia, A | 1 |
| Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L | 1 |
| Attitalla, IH | 1 |
| Adewale, AJ; Fazio, S; Guyton, JR; Jensen, E; Shah, A; Tershakovec, AM; Tomassini, JE | 1 |
| Bilal, R; Usman, A; Zakaria, M; Zia, A | 1 |
| Babageorgakas, P; Bouchliou, I; Kotsianidis, I; Margaritis, D; Miltiades, P; Nakou, E; Spanoudakis, E; Stakos, DA; Tziakas, DN | 1 |
| Vareka, T; Vecka, M; Vítková, D; Zák, A; Zeman, M | 1 |
| Covelli, D; Crisanti, F; De Vuono, S; Lupattelli, G; Mannarino, E; Pirro, M; Roscini, AR; Siepi, D | 1 |
| Hu, M; Mak, VW; Tomlinson, B | 1 |
| Chen, DY; Huang, X | 1 |
| Andersen, K; Björnsdóttir, LR; Einarsdóttir, R; Gizurarson, S; Halldórsson, M | 1 |
| Ginsberg, HN; Holleran, S; Karmally, W; Lovato, L; Ngai, CI; Ramakrishnan, R; Reyes-Soffer, G | 1 |
| Kiriliuk, IN; Kochetkova, EA; Semisotova, EF | 1 |
| Floras, JS; McGowan, CL; Millar, PJ; Morris, BL; Murai, H; Notarius, CF | 1 |
| Faergeman, O | 1 |
| Fu, Q; Gao, Y; Jia, M; Li, YP; Lu, PQ; Yang, SH; Zhang, LR | 1 |
| Chee, FY; How, CH | 1 |
| Vichayanrat, A | 1 |
| Bedford, D; Caslake, MJ; Forster, LF; Packard, CJ; Rogers, E; Shepherd, J; Stewart, G; Stewart, JP | 1 |
| DeGruiter, H; Lavie, CJ; Mehra, MR; Milani, RV; Uber, PA; Vivekananthan, K | 1 |
| Samuels, S; Thompson, M | 1 |
| Li, J; Liu, FY; Liu, YH; Zhu, XP | 1 |
| Hryszko, T; Małyszko, J; Małyszko, JS; Myśliwiec, M; Pawlak, K | 1 |
| Balon, HR; Rhodes, CA | 1 |
| Bays, HE; Maccubbin, DL; Mercuri, M; Mitchel, YB; Shah, AK; Stein, EA | 1 |
| Nordøy, A | 1 |
| Császár, A; Márk, L | 1 |
| Liu, H; Wu, G; Ye, X; Zhu, Y | 1 |
| Costache, G; Sima, A; Simionescu, M; Stancu, C | 1 |
| Gratsianskiĭ, NA | 1 |
| Anstey, AV; Holme, SA; Pearse, AD | 1 |
| Parmley, WW | 1 |
| Black, DM | 1 |
| Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE | 1 |
| Brzosko, S; Hryszko, T; Malyszko, J; Malyszko, JS; Mysliwiec, M | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Clark, LT | 1 |
| Danielson, C; Houseworth, J; Jackson, L; McCarthy, L; Skipworth, E | 1 |
| Cater, NB; Filipchuk, N; Garcia-Garcia, AB; Grundy, SM; Ma, PT; Meguro, S; Vega, GL | 1 |
| Chollet, ME; Pérez, J; Tristano, A | 1 |
| Chen, P; Li, G; Ran, X; Tian, H; Tong, N | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Kim, DS; Koh, KK; Park, GS; Shin, EK; Son, JW | 1 |
| Oguogho, A; Sinzinger, H | 1 |
| Belowski, D; Herman, ZS; Kalina, Z; Kowalski, J; Madej, A; Okopień, B; Zieliński, M | 1 |
| Chen, CC; Hong, RC; Ko, YS; Lu, CS; Severs, NJ; Shiao, MS; Tsai, CH; Wu, YJ; Yeh, HI | 1 |
| Alkhenizan, A | 1 |
| Bubnova, MG; Katel'nitskaia, LI; Kukharchuk, VV; Nikitin, IuP; Ol'binskaia, LI | 1 |
| Ito, MK; Pieper, JA; Talbert, RL | 1 |
| Ding, X; Shang, Y; Ye, P | 1 |
| Akhmedzhanov, NM; Metel'kaya, VA; Oganov, RG; Raszzivin, VA; Vasiutina, EI | 1 |
| Chasiotis, G; Elisaf, MS; Kakafika, A; Milionis, HJ; Papakostas, J; Seferiadis, K | 1 |
| Akahane, T; Fukui, H; Kuriyama, S; Mizushige, K; Nishio, H | 1 |
| Diener, HC | 1 |
| Burak, W; Grzeszczak, W; Gumprecht, J; Karasek, D; Kuźniewicz, R; Mosur, M; Otulski, I; Zychma, M; Zywiec, J | 1 |
| Ito, MK | 1 |
| Monaghan, MS; Skrabal, MZ; Stading, JA | 1 |
| Chan, CC; Chew, EY; Cusick, M; Ferris, FL; Kruth, HS; Murphy, RP | 1 |
| Bays, HE; McGovern, ME | 1 |
| Galper, JB; Kim, YJ; Park, HJ; Saul, JP; Shin, DG; Welzig, CM | 1 |
| Aleo, E; Dmitrieva, A; Littarru, GP; Passi, S; Stancato, A | 1 |
| Hsieh, ST; Ishikawa, Y; Kim, JI; Miki, T; Tanaka, S; Taniguchi, T; Yasumoto, T; Yokoyama, M | 1 |
| Makita, S; Oshima, K; Wajima, T | 1 |
| Danilogorskaia, IuA; Ol'binskaia, LI | 1 |
| Andrus, MR | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| McKenney, J | 1 |
| Ceska, R; Hilgertová, J; Kvasnicka, J; Skrha, J; Stulc, T; Weiserová, H | 1 |
| Kiselevich, A; London, D; Magen, E; Priluk, R; Viskoper, RJ; Volchek, L; Yosefy, C | 1 |
| Battisti, WP; Borisute, H; Dobs, A; Miller, M; Palmisano, J; Yuan, Z | 1 |
| Bilchick, KC; Blumenthal, RS; Henrikson, CA; Kasper, EK; Skojec, D | 1 |
| Białobrzeska-Paluszkiewicz, J; Grzybowska, B; Kłosiewicz-Latoszek, L; Stolarska, I; Szostak, WB; Wiśniewska, B | 1 |
| Lightfoot, JD; Mahmud, W; Shekhar, A; Webber, MA | 1 |
| Arias, M; Rodrigo, E; Valero, R; Zubimendi, JA | 1 |
| Ahn, JY; Ahn, TH; Choi, IS; Han, SH; Jeong, EM; Jin, DK; Kim, HS; Koh, KK; Shin, EK | 1 |
| Athyros, VG; Bairaktari, ET; Elisaf, MS; Kakafika, AI; Milionis, HJ; Seferiadis, KI; Tsouli, SG | 1 |
| Ford, MA; Jones, WN; Mangin, EF; Robles, GI; Thomson, SP | 1 |
| Gligor, E; Ossian, V; Pop, D; Zdrenghea, D | 1 |
| Emmett, L; Perera, C; Thanakrishnan, K; Trieu, J; Van Der Wall, H | 1 |
| Eroğlu, S; Korkmaz, ME; Müderrisoğlu, H; Ozin, B; Pirat, B; Tayfun, E; Uluçam, M; Yildirir, A | 1 |
| Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR | 1 |
| Li, Z; Liu, J; Luo, CH; Tan, ZR; Wang, A; Wang, LS; Yu, BN; Zhang, W; Zhou, G; Zhou, HH | 1 |
| Hasegawa, R; Hirata-Koizumi, M; Miyake, S; Saito, M; Urano, T | 1 |
| Bays, HE; Blasetto, JW; Cain, VA; Deedwania, PC; Hunninghake, DB; Jones, PH | 1 |
| Schäfer, J | 1 |
| Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L | 1 |
| Reasner, CA | 1 |
| Deeg, MA; Jacob, S; Jacob, SS; Williams, C | 1 |
| Kawamori, R; Miwa, S; Nishiyama, K; Omura, C; Onuma, T; Takayanagi, N; Tanaka, Y; Watada, H | 1 |
| Aberg, JA; Alston, BL; Brobst, SW; Fichtenbaum, CJ; Gerber, JG; Rosenkranz, SL; Segal, Y; Vega, JM; Yang, A | 1 |
| Fagen, N; Kasimian, D; Leung, FW; Lieberman, J; Wick, R | 1 |
| Badimon, L; Crespo, J; Martínez-González, J; Rius, J | 1 |
| Borisova, TI; Leshchinskiĭ, LA; Logacheva, IV; Shustova, EN; Zinov'eva, OA | 1 |
| Albertini, JP; Charniot, JC; Hantz, E; Le Moyec, L; Valensi, P | 1 |
| Hepfinger, CA; Sahni, S; Sauer, KA | 1 |
| Laport, G; Lowsky, R; Tong, J | 1 |
| Leis, AA; Olivier, J; Stokic, DS | 1 |
| Ichimaru, N; Imamura, R; Matsumiya, K; Moriyama, T; Namba, Y; Nonomura, N; Okuyama, A; Shi, Y; Takahara, S; Toki, K | 1 |
| Berglund, L; Ginsberg, HN; Holleran, S; Jones, J; Myerson, M; Ngai, C; Ramakrishnan, R | 1 |
| Kukharchuk, VV; Rozhkova, TA; Solov'eva, EIu; Susekov, AV; Titov, VN | 1 |
| Ferns, GA; Ghayour-Mobarhan, M; Lamb, DJ; Livingstone, C; Taylor, A; Vaidya, N; Wang, T | 1 |
| Hisatomi, K; Ide, M; Ishii, H; Ishimoto, H; Kakugawa, T; Kohno, S; Mukae, H; Nakayama, S; Sugiyama, K; Yoshioka, S | 1 |
| Briestensky, J; Jamborova, G; Jaynes, R; Kopecky, M; Nachtigal, P; Pospechova, K; Pospisilova, N; Santar, I; Semecky, V; Smahelova, A; Solichova, D; Zdansky, P | 1 |
| Kastelein, JJ; Sankatsing, RR | 1 |
| Ahn, HC; Ku, SK; Lee, HS | 1 |
| Gao, F; Hu, XF | 1 |
| Kawasaki, A; Kesler, A; Purvin, V; Smith, KH | 1 |
| Javorský, M; Molcányiová, A; Stancáková, A; Tkác, I | 1 |
| Fukuo, K; Katuya, T; Kawamoto, H; Kotani, N; Ogihara, T; Sugimoto, K; Suzuki, A; Takemura, Y; Yasuda, O; Yokoi, T | 1 |
| Li, Q; Wang, J; Wang, Y; Xu, Q; Zou, H | 1 |
| Bucek, RA; Minar, E; Pourazim, A; Reiter, M; Wirth, S | 1 |
| Ageev, FT; Chernina, GV; Iarovaia, EB; Kukharchuk, VV; Nuraliev, EIu; Orlova, IaA; Vitsenia, MV | 1 |
| Abraham, J; Alla, V; Bonkovsky, HL; Chalasani, NP; Raina, D; Siddiqui, J; Wu, GY | 1 |
| Martini, B | 1 |
| Li, Q; Wang, D; Wang, Y; Xu, Q | 1 |
| Movahed, MR; Samsamsharaiat, SA | 1 |
| Chang, LT; Chua, S; Fu, M; Sun, CK; Wu, CJ; Yip, HK | 1 |
| Chan, YH; Lim, SC; Sum, CF; Tavintharan, S | 1 |
| Davies, MJ; Farnier, M; Gil-Extremera, B; Hamlin, C; Kush, D; Macdonell, G; Mendez, GF; Mitchel, YB; Perevozskaya, I; Roth, E | 1 |
| Janíková, L; Stanková, B; Stopka, P; Tvrzická, E; Vareka, T; Vecka, M; Zahin, M; Zák, A; Zeman, M | 1 |
| Coleman, CI; Dale, KM; Kluger, J; Patel, AA; Shah, SA; White, CM | 1 |
| Cai, G; Du, L; Su, H; Wang, W; Xie, W; Xing, D | 1 |
| Hammervold, T; Howe, PR; Meyer, BJ; Rustan, AC | 1 |
| Chen, KJ; Guo, Y; Shi, DZ; Yin, HJ | 1 |
| Clarke, PJ; Grobler, MP; Levison, DB; Liew, D; Magliano, DJ; Rogers, SL; Webb, K | 1 |
| Balcerak, M; Broncel, M; Chojnowska-Jezierska, J | 1 |
| Adamus, J; Bak, A; Janczak, J; Kałka, D; Kopka, L; Korzeniowska, J; Marciniak, W; Popielewicz-Kautz, A; Sobieszczańska, M; Zawadzka-Bartczak, E | 1 |
| Glazer, R; Jia, Y; Kariisa, M; Pitt, B; Prescott, MF; Radauceanu, A; Rajagopalan, S; Zannad, F | 1 |
| Robinson, JG | 1 |
| Robins, DN | 1 |
| Dixit, RP; Nagarsenker, MS | 1 |
| Berthold, HK; Giannakidou, E; Gouni-Berthold, I; Gylling, H; Hallikainen, M; Ko, Y; Krone, W; Mantzoros, CS; Patel, D; Plat, J; Seedorf, U; Soutar, AK; Stier, S | 1 |
| Farnier, M | 2 |
| Kesäniemi, A | 1 |
| Borgström, F; Jönsson, B; Kanis, JA; Ström, O; Zethraeus, N | 1 |
| Bała, A; Broncel, M; Chojnowska-Jezierska, J; Duchnowicz, P; Koter-Michalak, M; Wojsznis, W | 1 |
| Rebrov, AP; Tolstov, CN | 1 |
| Guan, JZ; Matsui, J; Matsuki, K; Murakami, H; Suda, T; Tamasawa, N; Tanabe, J; Yamashita, M | 1 |
| Mamatsashvili, M; Mdivani, I | 1 |
| Sun, M; Yang, L; Yu, GL; Zhang, SD; Zhou, HY | 1 |
| Cokkinos, DV; Ioannis, V; Katerina, A; Kolovou, GD | 1 |
| Müderrisoğlu, H; Sezgin, AT; Tekin, A; Tekin, G | 1 |
| Chisholm, A; Crooke, M; Jackson, R; Mann, J; Neutze, J; North, D; Swinburn, B; White, H; Wilcox, J | 1 |
| Ravnskov, U | 1 |
| Jacobson, TA | 1 |
| Campana, C; Gavazzi, A; Iacona, I; Montemartini, C; Perani, G; Raddato, V; Regazzi, MB; Viganò, M | 1 |
| Boumendil, E; Tubert-Bitter, P | 1 |
| Abdalla, AH; al-Hawas, FA; al-Khader, AA; al-Sulaiman, MH; Mousa, DH; Rassoul, Z; Rehman, MA | 1 |
| Durrington, PN | 1 |
| Boumendil, EF | 1 |
| Shepherd, J | 1 |
| Alberti, KG; Dyer, RG; Laker, MF; Stewart, MW | 1 |
| Caterson, RJ; Ibels, LS; Mahony, JF; Ong, CS; Pollock, CA; Waugh, DA | 2 |
| Dabpetch, O; Jeamanukoolkit, N; Kakong, P; Koanantakul, B; Nontakanun, S; Yipintsoi, S | 1 |
| Castelluccio, A; Fiorini, F; Patrone, E | 1 |
| Hutchesson, AC; Jones, AF; Moran, A | 1 |
| Carmena, R | 1 |
| Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS | 1 |
| Erkelens, DW; Illingworth, DR; Keller, U; Thompson, GR; Tikkanen, MJ | 1 |
| Rosenson, RS; Stein, JH | 1 |
| Cremer, P; Seidel, D | 1 |
| Herings, RM; Leufkens, HG; Urquhart, J | 1 |
| Hoeg, JM; Nelson, LM; Robins, ED | 1 |
| Barbir, M; Galloway, D; Hunt, BJ; Ilsley, C; Mitchell, A; Taylor, A; Yacoub, M | 1 |
| Böhler, J; Eckardt, HG; Schollmeyer, P; Wanner, C; Wieland, H | 1 |
| Lu, ZL | 1 |
| Carrier, M; Cartier, R; Genest, J; Leclerc, Y; Pelletier, GB; Pelletier, LC | 1 |
| Martinez Hernandez, BE; Moorhead, JF; Persaud, JW; Varghese, Z | 1 |
| Cimino, R; Civardi, F; Maltagliati, L; Marangoni, R; Masi, F; Romei Longhena, G | 1 |
| Antoniou, S; Dimitriadis, A; Hatzisavvas, N; Kaldi, I; Pastore, F; Stangou, M | 1 |
| Martínez-Castelao, A | 1 |
| Coleman, JE; Watson, AR | 1 |
| Wray, R | 1 |
| Simons, LA | 1 |
| Ballantyne, CM; Bourge, RC; Domalik, LJ; Eisen, HJ; Fishbein, DP; Kubo, SH; Lake, KD; Radovancevic, B; Taylor, DO; Ventura, HO; Yancy, CW; Young, JB | 1 |
| Davie, AP; McMurray, JJ | 1 |
| Branchi, A; Fiorenza, AM; Gandini, R; Maraffi, F; Rovellini, A; Sommariva, D | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Johannesson, M; Jönsson, B | 1 |
| Birkenhäger, JC; De Heide, L; Deckers, JW; Hoogerbrugge, N; Jansen, H; Zillikens, MC | 2 |
| Isley, W; Rajeshawari, M; Tal, A | 1 |
| Best, J; Black, D; Bracs, P; d'Emden, M; Dart, A; Hamilton-Craig, I; Jerums, G; Nicholson, G; Sullivan, D; Tallis, G; West, M | 1 |
| Buchalter, M | 1 |
| Durrington, P | 1 |
| Jeck, T; Keller, U; Riesen, WF | 1 |
| Adkins, JC; Faulds, D | 1 |
| Castro, R; Fonseca, I; Guimarães, S; Henriques, AC; Pereira, MC; Pimentel, JP; Queirós, J; Sarmento, AM | 1 |
| Heidinger, K; Jovin, IS; Muller-Berghaus, G; Taborski, U | 1 |
| Garg, A | 1 |
| Berge, RK; Bønaa, KH; Hansen, JB; Ingebretsen, OC; Nilsen, H; Nordøy, A | 1 |
| Helve, E; Ilmonen, M; Kaarsalo, E; Kilkki, E; Laakso, M; Saltevo, J; Tikkanen, MJ | 1 |
| Galper, JB | 1 |
| Mabuchi, H | 1 |
| Davignon, J; Farnier, M | 1 |
| Alpert, NM; Fischman, AJ; Gewirtz, H; Huggins, GS; Pasternak, RC | 1 |
| Luc, G | 1 |
| Mehregan, DA; Mehregan, DR; Pakideh, S | 1 |
| Hamazaki, T; Jokaji, H; Kobayashi, M; Minami, S; Nakamura, N | 1 |
| Hall, RR | 1 |
| Pedersen, TR | 1 |
| de Lorgeril, M; Lacan, P; Paillard, F; Richard, G; Salen, P | 1 |
| Strandberg, TE; Tikkanen, MJ; Vanhanen, H | 1 |
| Belichard, P; Bontemps, L; de Lorgeril, M; Geyssant, A; Itti, R; Salen, P | 1 |
| Shestakova, MV | 1 |
| Barradell, LB; Goa, KL; McTavish, D | 1 |
| Girona, J; La Ville, AE; Masana, L; Plana, N; Solà, R | 1 |
| de Maat, MP; Gevers Leuven, JA; Kluft, C; Mohrschladt, MF; Potter van Loon, BJ | 1 |
| Alfon, J; Badimon, L; Pueyo Palazon, C; Royo, T | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Algra, A; Banga, JD; de Bruint, TW; Erkelens, DW; Kanters, SD | 1 |
| Basile, V; Capone, D; Gentile, A; Imperatore, P; Pellegrino, T; Stanziale, P | 1 |
| Cao, Z; Cooper, ME; Cox, AJ; Gilbert, RE; Jandeleit-Dahm, K; Kelly, DJ | 1 |
| Kimura, K; Kishino, M; Maeda, A; Maeda, T; Miyano, M; Mune, M; Nishide, I; Nishide, T; Nishikawa, O; Ogawa, A; Otani, H; Takahashi, T; Tone, Y; Yukawa, S | 1 |
| Guo, J; Kou, W; Lu, Z | 1 |
| Hoshide, S; Ikeda, U; Kario, K; Kobayashi, H; Matsuo, T; Mitsuhashi, T; Miyata, T; Mizuno, O; Sakata, T; Shimada, K | 1 |
| Aoki, T; Kitahara, M; Saito, Y; Sato, F; Suzuki, H; Tamaki, T | 1 |
| Poullis, M | 1 |
| Taskinen, MR | 1 |
| Brown, A; Hawley, C; Lepre, F; Rigby, R; Saltissi, D; Walsh, Z | 1 |
| Bonaa, KH; Hansen, JB; Nilsen, H; Nordoy, A; Sandset, PM | 1 |
| Bayindir, O; Celik, A; Habif, S; Mutaf, I; Ok, E; Unsal, A | 1 |
| Barbagallo, M; Barbieri, M; Giordano, M; Paolisso, G; Petrella, G; Ragno, E; Varricchio, M | 1 |
| Gavish, D; Leibovitz, E; Rubinstein, A; Shapira, I | 1 |
| Bisicchia, A; Di Salvo, MM; Ferlito, S; Gallina, M; Mugno, F | 1 |
| Coupal, L; Dorais, M; Grover, SA; Zowall, H | 1 |
| Bays, H; Davidson, M; Dujovne, C; Korenman, S; Mercuri, M; Plotkin, D; Stein, E; Stepanavage, M | 1 |
| Fugit, RV; Resch, ND | 1 |
| Chik, G; Crook, MA; Lumb, PJ; Wierzbicki, AS | 1 |
| Cromwell, W; Dolinar, C; Miller, M; Otvos, JD | 1 |
| Alexander, CM; Coupal, L; Gomes, DR; Grover, SA; Weiss, TW; Zowall, H | 1 |
| Lee, AJ; Maddix, DS | 1 |
| Chen, YT; Jeng, CY; Lee, WJ; Lin, SY; Pei, D; Sheu, WH | 1 |
| Goldner, D; Insull, W; Kafonek, S; Zieve, F | 1 |
| Avery, JK | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Grundy, SM; Jialal, I; Stein, D | 1 |
| Itakura, H | 2 |
| Egede, LE | 1 |
| De Gevigney, G; Delahaye, F | 1 |
| Tallis, GA | 1 |
| Albers, JJ; Brown, BG; Cheung, M; Marino, E; Morse, J; Zhao, XQ | 1 |
| Akhmedzhanov, NM; Oganov, RG; Olfer'ev, AM; Ozerova, IN; Paramonova, IV; Pavlova, LI; Perova, NV | 1 |
| Le, NA | 1 |
| Dresselhaus, TR; Henry, RR; Ito, MK; Lin, JC; Marcus, DB; Morreale, AP; Shabetai, R | 1 |
| Hatori, M; Ichimaru, N; Inoue, T; Kameoka, H; Kokado, Y; Okuyama, A; Takahara, S; Wang, JD | 1 |
| Bazalo, GR | 1 |
| Adams-Huet, B; Balis, D; Devaraj, S; Jialal, I; Stein, DT | 1 |
| Hromádka, M; Mayer, O | 1 |
| Platts, J | 1 |
| Garber, BG; McDonald, KB; Perreault, MM | 1 |
| Karalis, DG; Ross, AM; Scott, R; Vacari, RM; Zarren, H | 1 |
| Stein, EA | 1 |
| Arnadottir, M; Berg, AL; Dallongeville, J; Hardarson, A; Olafsdottir, E; Sigurdsson, G | 1 |
| Burgess, LJ; Marais, AD | 1 |
| de Boer, A; Fishman, PA; Heckbert, SR; Klungel, OH; Leufkens, HG; Psaty, BM; Sullivan, SD; Veenstra, DL | 1 |
| Mach, F | 1 |
| Karpe, F | 1 |
| Basit, A; Hakeem, R; Hydrie, MZ; Rehman, H | 1 |
| Chen, Z; Detmers, PA; Ehlers, R; Fukutomi, T; Rogers, C; Simon, DI; Wright, SD; Zago, AC | 1 |
| Angelé, B; Bellinghieri, G; Savica, V | 1 |
| Foo, WM; Lim, MC | 1 |
| Illingworth, DR | 1 |
| Harris, DC; Mitchell, P; Simons, LA; Stewart, JH | 1 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Galbraith, W; Watt, G | 1 |
| Abrignani, MG; Alaimo, G; Averna, MR; Barbagallo, CM; Davì, G; Marino, G; Notarbartolo, A; Novo, S; Strano, A | 1 |
| Brown, WV | 1 |
| Mol, MJ; Stalenhoef, AF; Stuyt, PM; van 't Laar, A | 1 |
| Erkelens, DW; Hené, RJ; Joles, JA; Koomans, HA; Rabelink, AJ | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
51 review(s) available for simvastatin and Hyperlipemia
| Article | Year |
|---|---|
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Topics: Asian People; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2019 |
Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.
Topics: Berberine; Cholesterol; Databases, Bibliographic; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Phytotherapy; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2019 |
Hyperlipidemia, tissue factor, coagulation, and simvastatin.
Topics: Animals; Blood Coagulation; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin; Thromboplastin; Thrombosis | 2014 |
[Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia].
Topics: Anticholesteremic Agents; Azetidines; Drug Synergism; Ezetimibe; Humans; Hyperlipidemias; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Chronotherapy versus conventional statins therapy for the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Drug Chronotherapy; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Defining the Place of Ezetimibe/Atorvastatin in the Management of Hyperlipidemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin | 2017 |
CD8+ cutaneous T-cell lymphoma successfully treated with bexarotene: a case report and review of the literature.
Topics: Antineoplastic Agents; Azetidines; Bexarotene; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Contraindications; Exanthema; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Incidental Findings; Kidney Neoplasms; Male; Middle Aged; Mycosis Fungoides; Neoplasms, Multiple Primary; Simvastatin; Skin Neoplasms; Tetrahydronaphthalenes; Thyroxine | 2008 |
Lipid-lowering effects of ezetimibe and simvastatin in combination.
Topics: Animals; Anticholesteremic Agents; Azetidines; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2011 |
Cost-effectiveness of statins revisited: lessons learned about the value of innovation.
Topics: Cardiovascular Diseases; Cost of Illness; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Prescriptions; Health Care Costs; Health Policy; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Quality-Adjusted Life Years; Risk Factors; Simvastatin; Sweden | 2012 |
A case study of single-pill combination therapy: the ezetimibe/simvastatin combination for treatment of hyperlipidemia.
Topics: Animals; Azetidines; Drug Combinations; Drug Discovery; Ezetimibe, Simvastatin Drug Combination; Heart Diseases; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2012 |
Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Diet; Docosahexaenoic Acids; Drug Combinations; Eicosapentaenoic Acid; Exercise; Fatty Acids, Omega-3; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
[Antilipemic agents in combined therapy].
Topics: Anticholesteremic Agents; Apolipoproteins; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Ezetimibe; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Folic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Pravastatin; Simvastatin; Triglycerides; Vitamin B 12; Vitamin B 6 | 2002 |
Treating dyslipidemia with statins: the risk-benefit profile.
Topics: Atorvastatin; Cholesterol; Cholesterol, HDL; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Simvastatin; Stroke; Triglycerides; United States | 2003 |
Role of the pharmacist in establishing lipid intervention programs.
Topics: Clinical Trials as Topic; Humans; Hyperlipidemias; Pharmacies; Pharmacists; Pharmacy Service, Hospital; Pravastatin; Program Development; Simvastatin; United States | 2003 |
Oral anticoagulant drug interactions with statins: case report of fluvastatin and review of the literature.
Topics: Acenocoumarol; Administration, Oral; Aged; Anticoagulants; Atorvastatin; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; International Normalized Ratio; Male; Patient Compliance; Pyrroles; Simvastatin; Venous Thrombosis; Warfarin | 2004 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin | 2004 |
New perspectives on the use of niacin in the treatment of lipid disorders.
Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Simvastatin | 2004 |
Treatment of hyperlipidemia in cardiac transplant recipients.
Topics: Algorithms; Coronary Artery Disease; Endothelium, Vascular; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Pravastatin; Simvastatin | 2004 |
Commentary: A new approach to atherogenic dyslipidemia.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Niacin; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2005 |
Guggulipid use in hyperlipidemia: case report and review of the literature.
Topics: Commiphora; Diarrhea; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Plant Extracts; Plant Gums; Randomized Controlled Trials as Topic; Simvastatin | 2005 |
Statins and polyneuropathy: setting the record straight.
Topics: Global Health; Humans; Hyperlipidemias; Hypolipidemic Agents; Incidence; Polyneuropathies; Risk Factors; Simvastatin | 2005 |
Ezetimibe/simvastatin (INEGY) in the treatment of hyperlipidaemia.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Treatment Outcome | 2005 |
Statin-associated myasthenia gravis: report of 4 cases and review of the literature.
Topics: Aged; Autoantibodies; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myasthenia Gravis; Pravastatin; Pyrimidines; Receptors, Cholinergic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2006 |
Impact of gender on statin efficacy.
Topics: Age Distribution; Aged; Cardiovascular Diseases; Comorbidity; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Male; Middle Aged; Odds Ratio; Pravastatin; Probability; Prognosis; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Severity of Illness Index; Sex Distribution; Simvastatin; Survival Analysis; Treatment Outcome | 2007 |
A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2007 |
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Niacin; Risk Factors; Simvastatin | 2007 |
Simvastatin: present and future perspectives.
Topics: Animals; Cardiovascular Diseases; Cholesterol, LDL; Forecasting; Humans; Hyperlipidemias; Simvastatin | 2007 |
Setting a new standard in achieving superior efficacy: ezetimibe + simvastatin.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Simvastatin; Treatment Outcome | 2007 |
Cholesterol absorption inhibitors in the treatment of hyperlipidemia: clinical outcomes in large clinical trials.
Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Simvastatin; Treatment Outcome | 2007 |
Simvastatin: two decades in a circle.
Topics: Animals; Anti-Inflammatory Agents; Cardiovascular Diseases; Endothelial Cells; Endothelium, Vascular; Hemostasis; History, 20th Century; History, 21st Century; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipoproteins, LDL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Simvastatin; Treatment Outcome | 2008 |
Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety.
Topics: Clinical Trials as Topic; Clofibrate; Drug Therapy, Combination; Humans; Hyperlipidemias; Lovastatin; Pravastatin; Retrospective Studies; Simvastatin | 1995 |
[Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
Topics: Anticholesteremic Agents; Cardiovascular System; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipoproteins; Lovastatin; Pravastatin; Simvastatin | 1995 |
Treatment of lipids. Implications for the general practitioner.
Topics: Family Practice; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1996 |
Treatment of hyperlipidemia after heart transplantation and rationale for the Heart Transplant Lipid Registry.
Topics: Anticholesteremic Agents; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Postoperative Complications; Pravastatin; Registries; Simvastatin; Treatment Outcome | 1996 |
Statins and fibrates in the management of diabetic dyslipidemia.
Topics: Diabetes Complications; Diabetes Mellitus; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1997 |
Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Diabetes Complications; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Tolerance; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Pravastatin; Simvastatin | 1997 |
Treatment of diabetic dyslipidemia.
Topics: Cholesterol, Dietary; Cholesterol, LDL; Clinical Trials as Topic; Combined Modality Therapy; Coronary Disease; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Eicosapentaenoic Acid; Estrogen Replacement Therapy; Exercise; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Lipoproteins, VLDL; Postmenopause; Risk Factors; Simvastatin; Weight Gain | 1998 |
[Hyperlipidemia and arteriosclerosis].
Topics: Anticholesteremic Agents; Coronary Artery Disease; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Pravastatin; Simvastatin | 1998 |
Current and future treatment of hyperlipidemia: the role of statins.
Topics: Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pyridines; Safety; Simvastatin; Treatment Outcome | 1998 |
Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
Topics: Coronary Disease; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Role of hyperlipidemia in progressive renal disease: focus on diabetic nephropathy.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Clinical Trials as Topic; Diabetic Nephropathies; Disease Progression; Gene Expression; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Situ Hybridization; Kidney Diseases; Kidney Glomerulus; Lovastatin; Male; Nephrectomy; Pravastatin; Pyrroles; Rats; Rats, Sprague-Dawley; Simvastatin; Transforming Growth Factor beta | 1999 |
Strategies for the management of diabetic dyslipidaemia.
Topics: Arteriosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Risk Factors; Simvastatin | 1999 |
[The hyperlipidemias. Role of various statins].
Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Pravastatin; Pyridines; Pyrroles; Simvastatin | 1999 |
Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Interactions; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Rhabdomyolysis; Simvastatin; Sinusitis | 2001 |
Statin therapy--what now?
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hyperlipidemias; Indoles; Patient Selection; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
[J-LIT [Japan Lipid Intervention Trial]].
Topics: Adult; Aged; Clinical Trials as Topic; Cohort Studies; Coronary Disease; Female; Follow-Up Studies; Humans; Hyperlipidemias; Japan; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Prospective Studies; Risk; Simvastatin | 2001 |
[Secondary prevention of coronary artery disease with lipid-lowering drugs].
Topics: Age Distribution; Age Factors; Aged; Aged, 80 and over; Cause of Death; Cholesterol; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Morbidity; Myocardial Revascularization; Patient Selection; Pravastatin; Risk Factors; Simvastatin; Treatment Outcome | 2001 |
Managing dyslipidemia in the high-risk patient.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Niacin; Practice Guidelines as Topic; Pravastatin; Pyrimidines; Pyrroles; Risk; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; United States | 2002 |
Postprandial lipemia--effect of lipid-lowering drugs.
Topics: Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Postprandial Period; Simvastatin | 2002 |
Clinical implications of new drugs for lowering plasma cholesterol concentrations.
Topics: Anticholesteremic Agents; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Lovastatin; Naphthalenes; Pravastatin; Simvastatin | 1991 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
125 trial(s) available for simvastatin and Hyperlipemia
| Article | Year |
|---|---|
Insulin Prevents Hypercholesterolemia by Suppressing 12α-Hydroxylated Bile Acids.
Topics: Animals; Bile Acids and Salts; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 1; Ezetimibe; Humans; Hypercholesterolemia; Hyperlipidemias; Insulin; Liver; Mice; Receptor, Insulin; Simvastatin; Steroid 12-alpha-Hydroxylase | 2022 |
Effects of Simvastatin on Plasma Amyloid-β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Peptide Fragments; Simvastatin; Triglycerides | 2022 |
Warm-needling acupuncture and medicinal cake-separated moxibustion for hyperlipidemia: study protocol for a randomized controlled trial.
Topics: Acupuncture Therapy; Adolescent; Adult; Aged; Biomarkers; China; Cholesterol, HDL; Cholesterol, LDL; Clinical Protocols; Female; Hot Temperature; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Middle Aged; Moxibustion; Needles; Research Design; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2017 |
Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study.
Topics: Aged; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leukocytes, Mononuclear; Male; MicroRNAs; Middle Aged; Pilot Projects; Simvastatin | 2018 |
Associations of the SLCO1B1 Polymorphisms With Hepatic Function, Baseline Lipid Levels, and Lipid-lowering Response to Simvastatin in Patients With Hyperlipidemia.
Topics: Aged; Alleles; Female; Haplotypes; Humans; Hyperlipidemias; Lipids; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Polymorphism, Genetic; Simvastatin | 2018 |
A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.
Topics: Adolescent; Adult; Child; Cytochrome P-450 CYP3A; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Models, Biological; Simvastatin; Young Adult | 2019 |
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
Topics: Aged; Azetidines; Biomarkers; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Simvastatin; Time Factors; Treatment Outcome | 2013 |
[Effects of policosanol combined with simvastatin on serum lipids and sex hormones in male patients with hyperlipidemia].
Topics: Adult; Aged; Drug Therapy, Combination; Fatty Alcohols; Gonadal Steroid Hormones; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Simvastatin; Single-Blind Method | 2013 |
Genetic algorithm guided population pharmacokinetic model development for simvastatin, concurrently or non-concurrently co-administered with amlodipine.
Topics: Adult; Aged; Algorithms; Amlodipine; Drug Interactions; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Models, Biological; Simvastatin | 2014 |
A pragmatic randomized trial of a polypill-based strategy to improve use of indicated preventive treatments in people at high cardiovascular disease risk.
Topics: Administration, Oral; Adrenergic beta-1 Receptor Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Atenolol; Australia; Biomarkers; Blood Pressure; Cardiovascular Diseases; Cholesterol; Drug Combinations; Drugs, Generic; Female; General Practice; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lisinopril; Male; Middle Aged; Platelet Aggregation Inhibitors; Polypharmacy; Primary Prevention; Prospective Studies; Risk Factors; Simvastatin; Sodium Chloride Symporter Inhibitors; Tablets; Time Factors; Treatment Outcome | 2015 |
Multifactorial intervention to prevent cardiovascular disease in patients with early rheumatoid arthritis: protocol for a multicentre randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Albuminuria; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Cardiovascular Diseases; Denmark; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Research Design; Risk Factors; Severity of Illness Index; Simvastatin; Young Adult | 2016 |
Endothelial Effect of Statin Therapy at a High Dose Versus Low Dose Associated with Ezetimibe.
Topics: Adult; Analysis of Variance; Anticholesteremic Agents; Brachial Artery; Cholesterol, LDL; Double-Blind Method; Endothelium, Vascular; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Placebo Effect; Reference Values; Simvastatin; Statistics, Nonparametric; Time Factors; Treatment Outcome; Vasodilation | 2016 |
[A clinical research of Naoxinqing tablet's effects on blood fat and viscosity].
Topics: Adult; Aged; Blood Viscosity; Cholesterol; Diospyros; Drugs, Chinese Herbal; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Middle Aged; Phytotherapy; Plant Leaves; Plants, Medicinal; Simvastatin; Tablets; Treatment Outcome; Triglycerides | 2008 |
VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.
Topics: Adult; Aged; Azetidines; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Middle Aged; Simvastatin | 2008 |
Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Azetidines; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Activation; Ezetimibe; Female; Humans; Hyperlipidemias; Leukocytes; Male; Middle Aged; Prospective Studies; rho-Associated Kinases; Simvastatin; Triglycerides; Vasculitis; Vasodilation | 2009 |
Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders.
Topics: Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Diseases; Pilot Projects; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2009 |
Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia.
Topics: Adult; Animals; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Lipoproteins; Male; Placebos; Simvastatin; Treatment Outcome; Triglycerides | 2009 |
Rationale and design of the Study Assessing the Effect of Cardiovascular Medications Provided as Low-cost, Evidence-based Generic Samples (SAMPLES) trial.
Topics: Diuretics; Drug Costs; Drug Prescriptions; Drugs, Generic; Humans; Hydrochlorothiazide; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Pennsylvania; Physicians, Family; Prescription Drugs; Simvastatin | 2009 |
A randomized, controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: the Secondary Prevention of Acute Coronary Events--Reduction of Cholesterol to Key European Targets Trial.
Topics: Aged; Biomarkers; Cholesterol; Cholesterol, LDL; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Practice Guidelines as Topic; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Secondary Prevention; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United Kingdom | 2009 |
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose (20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in End-Points Through Aggressive Lipid-Lowering (IDEAL) trial.
Topics: Administration, Oral; Aged; Aged, 80 and over; Atorvastatin; Canada; Cardiovascular Diseases; Confidence Intervals; Cost of Illness; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Health Care Costs; Heptanoic Acids; Hospitalization; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Markov Chains; Middle Aged; Myocardial Infarction; Probability; Pyrroles; Risk Assessment; Simvastatin; Survival Rate; Treatment Outcome | 2009 |
Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.
Topics: Adolescent; Adult; Aged; Alleles; Anticholesteremic Agents; Apolipoprotein E3; Atorvastatin; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Cholesterol, LDL; Dose-Response Relationship, Drug; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Regression Analysis; Simvastatin | 2008 |
Effects of statins vs. non-statin lipid-lowering therapy on bone formation and bone mineral density biomarkers in patients with hyperlipidemia.
Topics: Aged; Bone Density; Bone Diseases, Metabolic; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Osteogenesis; Patient Selection; Prospective Studies; Simvastatin; Treatment Outcome | 2010 |
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Niacin; Severity of Illness Index; Simvastatin; Tennessee; Time Factors; Treatment Outcome; Vitamin B Complex | 2010 |
Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Topics: Aged; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Probability; Risk Assessment; Severity of Illness Index; Simvastatin; Treatment Outcome | 2010 |
CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.
Topics: Alleles; Asian People; Atorvastatin; China; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Restriction Fragment Length; Prospective Studies; Pyrroles; Sex Factors; Simvastatin | 2011 |
Non-concurrent dosing attenuates the pharmacokinetic interaction between amlodipine and simvastatin.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Area Under Curve; Drug Administration Schedule; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Simvastatin | 2010 |
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Niacin; Simvastatin; Treatment Outcome | 2010 |
[Randomized comparative study on the lipid lowering effects of Zhikang Granule and simvastatin].
Topics: Aged; C-Reactive Protein; Drugs, Chinese Herbal; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Phytotherapy; Simvastatin | 2010 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Lipid lowering efficacy between morning and evening simvastatin treatment: a randomized double-blind study.
Topics: Adolescent; Adult; Aged; C-Reactive Protein; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Treatment Outcome; Young Adult | 2010 |
Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
Topics: Aged; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Female; Fenofibrate; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin | 2011 |
Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
Topics: Aged; Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2012 |
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome | 2013 |
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
Topics: Adolescent; Adult; Age of Onset; Aged; Azetidines; Delayed-Action Preparations; Diabetes Complications; Diabetes Mellitus; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Niacin; Simvastatin; Time Factors; Young Adult | 2012 |
Statin-induced immunomodulation alters peripheral invariant natural killer T-cell prevalence in hyperlipidemic patients.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunomodulation; Male; Middle Aged; Natural Killer T-Cells; Prevalence; Simvastatin; Triglycerides | 2012 |
Cholesterol metabolism differs after statin therapy according to the type of hyperlipemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Female; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemia, Familial Combined; Hyperlipidemias; Lipids; Male; Middle Aged; Phytosterols; Pyrroles; Simvastatin; Sitosterols | 2012 |
Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial.
Topics: Aged; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period; Simvastatin | 2013 |
Simvastatin reduces sympathetic outflow and augments endothelium-independent dilation in non-hyperlipidaemic primary hypertension.
Topics: Arteries; Blood Pressure; Cross-Over Studies; Double-Blind Method; Endothelium, Vascular; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Male; Middle Aged; Prospective Studies; Simvastatin; Sympathetic Nervous System; Vasodilation | 2013 |
Dose-expanded study in the reinforcement of efficacy of simvastatin.
Topics: Adult; Aged; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Simvastatin | 2002 |
Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
Topics: Adult; Apolipoproteins B; Cross-Over Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 2002 |
Comparison of the efficacy and safety of pravastatin and simvastatin in heart transplantation.
Topics: Adult; Cholesterol; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 2002 |
[Effects on simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia].
Topics: Adult; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 2000 |
Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.
Topics: Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Predictive Value of Tests; Serum Amyloid A Protein; Simvastatin; Statistics as Topic; Treatment Outcome; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2002 |
[The effects of tablet tongmaijiangzhi on hyperlipidemia and nitric oxide of patients with non-insulin-dependent diabetes mellitus].
Topics: Aged; Apolipoproteins; Blood Viscosity; Diabetes Mellitus, Type 2; Drugs, Chinese Herbal; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Nitric Oxide; Phytotherapy; Simvastatin; Tablets; Triglycerides | 2002 |
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Time Factors | 2003 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Simvastatin | 2003 |
[A multicenter randomized controlled clinical trial on lipids regulating effects of domestic simvastatin].
Topics: Adult; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2001 |
Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.
Topics: Atorvastatin; Cells, Cultured; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Monocytes; Pyrroles; Simvastatin | 2003 |
[Efficacy and safety of simvastatin in patients with hypercholesterolemia (results of a Multicenter Clinical Study)].
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Ischemia; Safety; Simvastatin; Time Factors; Triglycerides | 2003 |
Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.
Topics: Analysis of Variance; Atorvastatin; Blood Glucose; Female; Fenofibrate; Heptanoic Acids; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2003 |
Lipid lowering by pravastatin increases parasympathetic modulation of heart rate: Galpha(i2), a possible molecular marker for parasympathetic responsiveness.
Topics: Adult; Aged; Biomarkers; Blotting, Western; Cross-Over Studies; Electrocardiography, Ambulatory; Female; GTP-Binding Protein alpha Subunit, Gi2; GTP-Binding Protein alpha Subunits, Gi-Go; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lymphocytes; Male; Middle Aged; Parasympathetic Nervous System; Pravastatin; Predictive Value of Tests; Proto-Oncogene Proteins; Simvastatin; Single-Blind Method | 2003 |
[Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
Topics: Cholesterol; Drug Costs; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2003 |
Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.
Topics: Acetylglucosaminidase; Adult; Aged; alpha-Tocopherol; Ascorbic Acid; Cholesterol; Czech Republic; Diabetes Mellitus, Type 2; Drug Administration Schedule; E-Selectin; Endothelium; Female; Fenofibrate; Fibrinolysis; Glutathione; Humans; Hyperlipidemias; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Plasminogen Activator Inhibitor 1; Simvastatin; Superoxide Dismutase; Time Factors; Triglycerides; Vascular Endothelial Growth Factor A; von Willebrand Factor | 2004 |
Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity.
Topics: Administration, Oral; Albuminuria; Blood Glucose; Blood Pressure; Body Mass Index; Brachial Artery; Cholesterol, LDL; Cilazapril; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Endothelial Cells; Endothelium, Vascular; Evoked Potentials; Female; Glyburide; Glycated Hemoglobin; Heart Rate; Humans; Hyperlipidemias; Hypertension; Insulin; Insulin Resistance; Kidney; Male; Rosiglitazone; Simvastatin; Skin Physiological Phenomena; Sympathetic Nervous System; Thiazolidinediones; Time Factors; Ultrasonography; Vasodilation | 2004 |
Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C.
Topics: Adult; C-Reactive Protein; Cholesterol, HDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin; Treatment Outcome | 2004 |
Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.
Topics: Brachial Artery; Coronary Artery Disease; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Matrix Metalloproteinases; Middle Aged; Nitrates; Nitric Oxide; Simvastatin; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha; Vasodilation | 2004 |
Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.
Topics: Atorvastatin; Female; Heptanoic Acids; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Logistic Models; Male; Middle Aged; Pyrroles; Simvastatin; Uric Acid | 2004 |
Comparing hyperlipidemia control with daily versus twice-weekly simvastatin.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Patient Satisfaction; Simvastatin | 2004 |
The effect of simvastatin associated with ranitidine and alcohol upon serum lipids.
Topics: Adult; Aged; Drug Therapy, Combination; Ethanol; Female; Histamine H2 Antagonists; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Ranitidine; Simvastatin; Treatment Outcome | 2004 |
[The effects of simvastatin combined with different antioxidant vitamin regimens on serum lipid profile in patients with low HDL cholesterol levels].
Topics: Administration, Oral; Antioxidants; Ascorbic Acid; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Simvastatin; Treatment Outcome; Vitamin E | 2004 |
Ile118Val genetic polymorphism of CYP3A4 and its effects on lipid-lowering efficacy of simvastatin in Chinese hyperlipidemic patients.
Topics: Adult; Aged; Asian People; China; Cholesterol; Cortisone; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gene Frequency; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Isoleucine; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Simvastatin; Triglycerides; Valine | 2005 |
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Arteriosclerosis; Atorvastatin; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2005 |
Effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of AIDS Clinical Trials Group 5108 Study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atorvastatin; Benzoxazines; Cholesterol, LDL; Cyclopropanes; Drug Interactions; Female; Heptanoic Acids; HIV Infections; HIV Seronegativity; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Oxazines; Pravastatin; Pyrroles; Simvastatin | 2005 |
[Statins: the clinical and metabolic effects in patients with unstable and stable angina].
Topics: Adult; Aged; Angina, Unstable; Anticholesteremic Agents; Electrocardiography; Female; Humans; Hyperlipidemias; Lipid Peroxidation; Male; Middle Aged; Simvastatin | 2005 |
Serum 1H-nuclear magnetic spectroscopy followed by principal component analysis and hierarchical cluster analysis to demonstrate effects of statins on hyperlipidemic patients.
Topics: Aged; Atorvastatin; Cholesterol; Cluster Analysis; Coronary Disease; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Multivariate Analysis; Nuclear Magnetic Resonance, Biomolecular; Principal Component Analysis; Pyrroles; Reproducibility of Results; Simvastatin | 2005 |
Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus.
Topics: Adult; Cyclosporine; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Lipids; Male; Pilot Projects; Prognosis; Simvastatin; Tacrolimus; Time Factors; Treatment Outcome | 2005 |
Treatment with high-dose simvastatin reduces secretion of apolipoprotein B-lipoproteins in patients with diabetic dyslipidemia.
Topics: Aged; Apolipoproteins B; Cross-Over Studies; Diabetes Complications; Female; Humans; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2005 |
[Efficacy and tolerability of statins in patients with primary hyperlipidemias].
Topics: Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 2005 |
Effect of Taizhi'an capsule combined with Simvastatin on hyperlipidemia in diabetic patients.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Phytotherapy; Simvastatin; Triglycerides | 2006 |
Fas ligand mRNA levels of circulating leukocytes reflect endothelial dysfunction in hyperlipidemic but not in non-hyperlipidemic patients.
Topics: Aged; Apoptosis; Atherosclerosis; Biomarkers; Brachial Artery; Endothelium, Vascular; Fas Ligand Protein; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Jurkat Cells; Leukocytes; Lipoproteins, LDL; Male; Membrane Glycoproteins; Middle Aged; Predictive Value of Tests; Regional Blood Flow; RNA, Messenger; Simvastatin; Tumor Necrosis Factors; Up-Regulation; Vasculitis | 2006 |
[Controlled administration of simvastatin and common therapy of hyperlipidemia in patients with ischemic heart disease in outpatient conditions: comparative investigation of two strategies (SIGNAL-CONTROL)].
Topics: Aged; Dose-Response Relationship, Drug; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Myocardial Ischemia; Simvastatin; Treatment Outcome | 2006 |
Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.
Topics: Azetidines; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe, Simvastatin Drug Combination; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2007 |
[Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].
Topics: Adult; Aged; Atorvastatin; Diabetes Mellitus, Type 2; Endothelium, Vascular; Fatty Acids, Omega-3; Female; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Middle Aged; Oxidative Stress; Pyrroles; Simvastatin | 2006 |
Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects.
Topics: Animals; Apolipoproteins B; Atorvastatin; Cholesterol, LDL; Dietary Fats; Dietary Fats, Unsaturated; Dietary Supplements; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Female; Fish Oils; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lipid Metabolism; Lipids; Lipoproteins, IDL; Lipoproteins, VLDL; Male; Middle Aged; Pyridines; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
[Effect of long-term cardiac training on lipids concentration in patients with chronic heart ischemic disease treated with simvastatin].
Topics: Aged; Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Exercise; Exercise Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Simvastatin; Treatment Outcome; Triglycerides | 2007 |
Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
Topics: Antihypertensive Agents; Biomarkers; Blood Pressure Monitoring, Ambulatory; C-Reactive Protein; Chemokine CCL2; Double-Blind Method; Drug Combinations; Drug Synergism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Tetrazoles; Valine; Valsartan | 2007 |
Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Gene Expression Regulation, Enzymologic; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Lipase; Male; Membrane Proteins; Membrane Transport Proteins; Proprotein Convertase 9; Proprotein Convertases; Prospective Studies; Receptors, LDL; Serine Endopeptidases; Simvastatin | 2008 |
Physicochemical modifications induced by statins therapy on human erythrocytes membranes.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Erythrocyte Membrane; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pyrroles; Simvastatin; Sodium-Potassium-Exchanging ATPase; Triglycerides | 2007 |
[Clinical efficacy and safety of Zo-20 in patients with ischemic heart disease].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Simvastatin; Treatment Outcome | 2008 |
Efficacy and pharmacokinetics of simvastatin in heart transplant recipients.
Topics: Adult; Cholesterol; Cyclosporine; Drug Interactions; Female; Heart Transplantation; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppression Therapy; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
Effects of simvastatin in hyperlipidemic renal transplant patients receiving cyclosporine.
Topics: Adolescent; Adult; Cyclosporine; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia.
Topics: Apolipoproteins B; Bezafibrate; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Phospholipids; Placebos; Pyrazines; Simvastatin; Triglycerides | 1995 |
Early response of hyperlipidemic subjects to simvastatin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1994 |
Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Probucol; Renal Dialysis; Simvastatin | 1994 |
The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Topics: Adult; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Forearm; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Probucol; Regional Blood Flow; Simvastatin; Vitamin E | 1994 |
A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting.
Topics: Analysis of Variance; Bezafibrate; Colestipol; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Factor VII; Factor VIII; Female; Fibrinogen; Fibrinolysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1994 |
Effects of simvastatin on lipoprotein (a) and lipoprotein composition in patients with nephrotic syndrome.
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoprotein(a); Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Simvastatin | 1994 |
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients.
Topics: Adult; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Postoperative Complications; Simvastatin; Single-Blind Method; Triglycerides | 1993 |
[Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
Topics: Anticholesteremic Agents; Drug Tolerance; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Pravastatin; Simvastatin | 1995 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome; Triglycerides | 1997 |
A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients with hypercholesterolemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Arthralgia; Atorvastatin; Cholesterol; Cholesterol, Dietary; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperhidrosis; Hyperlipidemias; Lovastatin; Male; Middle Aged; Patient Education as Topic; Pyrroles; Simvastatin; Triglycerides | 1997 |
Comparison of bezafibrate and simvastatin in the treatment of dyslipidaemia in patients with NIDDM.
Topics: Aged; Apolipoproteins; Bezafibrate; Creatine Kinase; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fibrinogen; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged; Patient Compliance; Simvastatin | 1997 |
Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil.
Topics: Adult; Female; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lipids; Male; Middle Aged; Postoperative Complications; Simvastatin; Treatment Outcome | 1997 |
Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia.
Topics: Adult; Combined Modality Therapy; Double-Blind Method; Fatty Acids, Omega-3; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Male; Middle Aged; Simvastatin; Treatment Outcome | 1998 |
Treatment of hypercholesterolemia and combined hyperlipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study.
Topics: Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Finland; Gemfibrozil; Glycated Hemoglobin; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1998 |
The additional effects of acipimox to simvastatin in the treatment of combined hyperlipidaemia.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Treatment Outcome | 1998 |
Effect of HMG-CoA reductase inhibitors on plasma polyunsaturated fatty acid concentrations in patients with hyperlipidemia.
Topics: Aged; Cholesterol; Coronary Disease; Diabetes Mellitus, Type 2; Fatty Acids, Unsaturated; Female; Glyburide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Male; Middle Aged; Pravastatin; Simvastatin; Triglycerides | 1998 |
Lipid-lowering drugs and homocysteine.
Topics: Amino Acids; Coronary Disease; Double-Blind Method; Fenofibrate; Homocysteine; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Simvastatin | 1999 |
Effect of statins on C-reactive protein in patients with coronary artery disease.
Topics: Adult; Aged; Atorvastatin; C-Reactive Protein; Cholesterol; Coronary Disease; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Simvastatin; Triglycerides | 1999 |
Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients.
Topics: Blood Pressure; Cholesterol, LDL; Coronary Disease; Double-Blind Method; Dyspepsia; Exercise Test; Female; Fenofibrate; Fibrinogen; Heart Rate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Patient Dropouts; Physical Endurance; Simvastatin; Stroke Volume; Treatment Outcome; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1999 |
Intensive lipid-lowering strategy in patients with diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diet; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pyrazines; Simvastatin; Triglycerides | 1999 |
Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Male; Pravastatin; Simvastatin | 1999 |
Effect of simvastatin on the lipid profile of hemodialysis patients.
Topics: Aged; Apolipoproteins B; Apolipoproteins E; Cholesterol; Cholesterol, VLDL; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Lipids; Male; Malondialdehyde; Middle Aged; Renal Dialysis; Simvastatin; Treatment Outcome; Triglycerides | 1999 |
[Effect of xuezhikang on the treatment of primary hyperlipidemia].
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1997 |
A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients.
Topics: Adolescent; Adult; Aged; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Simvastatin | 1999 |
Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia.
Topics: Adult; Blood Glucose; Dietary Fats; Double-Blind Method; Eating; Factor VIIa; Fatty Acids, Omega-3; Female; Hemostasis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Risk Factors; Simvastatin; Thrombosis | 2000 |
Which dosage of simvastatin in renal transplant patients?
Topics: Adult; Cyclosporine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Simvastatin | 2000 |
Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients.
Topics: Aged; Atorvastatin; Calorimetry, Indirect; Carbon Dioxide; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Energy Metabolism; Female; Glycated Hemoglobin; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Male; Oxygen Consumption; Pyrroles; Simvastatin; Single-Blind Method; Triglycerides | 2000 |
Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety.
Topics: Aged; Bezafibrate; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome | 2000 |
Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Apolipoprotein A-I; Cholesterol; Cross-Over Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Triglycerides | 2000 |
High-density lipoprotein cholesterol and triglyceride response with simvastatin versus atorvastatin in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Cross-Over Studies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hyperlipoproteinemia Type II; Male; Middle Aged; Pyrroles; Regression Analysis; Simvastatin; Triglycerides | 2000 |
Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.
Topics: Drug Administration Schedule; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Magnetic Resonance Spectroscopy; Simvastatin | 2001 |
Simvastatin treatment on postprandial hypertriglyceridemia in type 2 diabetes mellitus patients with combined hyperlipidemia.
Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Fasting; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Postprandial Period; Simvastatin; Triglycerides | 2001 |
Comparison of efficacy and safety of atorvastatin (10mg) with simvastatin (10mg) at six weeks. ASSET Investigators.
Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Diabetes Mellitus, Type 2; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Treatment Outcome | 2001 |
Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.
Topics: Atorvastatin; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Interleukin-6; Male; Middle Aged; Pravastatin; Pyrroles; Receptors, Interleukin-6; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus.
Topics: Adult; Apolipoproteins; Cholesterol; Cyclosporine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Lipids; Lipoproteins; Male; Prospective Studies; Simvastatin; Tacrolimus | 2001 |
Effect of statin therapy on remnant lipoprotein cholesterol levels in patients with combined hyperlipidemia.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Triglycerides | 2001 |
[Statins in the treatment of patients with arterial occlusive disease of the lower extremities].
Topics: Adult; Aged; Arteriosclerosis Obliterans; Blood Pressure; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Intermittent Claudication; Leg; Lipids; Male; Middle Aged; Simvastatin | 2001 |
Comparison of efficacy and safety of atorvastatin and simvastatin in patients with dyslipidemia with and without coronary heart disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Coronary Disease; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Patient Compliance; Prospective Studies; Pyrroles; Simvastatin; Treatment Outcome | 2002 |
[Results of clinical epidemiology and intervention trial of hyperlipidemia in Japan].
Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Japan; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Review of clinical studies of fenofibrate in combination with currently approved lipid-lowering drugs.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Colestipol; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Lovastatin; Nicotinic Acids; Propionates; Simvastatin | 1989 |
Effects of simvastatin and cholestyramine on lipoprotein profile in hyperlipidaemia of nephrotic syndrome.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Lovastatin; Male; Middle Aged; Nephrotic Syndrome; Random Allocation; Simvastatin | 1988 |
236 other study(ies) available for simvastatin and Hyperlipemia
| Article | Year |
|---|---|
Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.
Topics: Animals; Benzofurans; Carboxylic Acids; Cholesterol; Cricetinae; Dogs; Humans; Hyperlipidemias; Hypolipidemic Agents; In Vitro Techniques; Male; Mesocricetus; Molecular Conformation; PPAR alpha; Radioligand Assay; Stereoisomerism; Structure-Activity Relationship; Transcriptional Activation; Triglycerides | 2005 |
Design and synthesis of novel, conformationally restricted HMG-CoA reductase inhibitors.
Topics: Animals; Cholesterol; Drug Design; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Mice; Molecular Biology; Molecular Structure; Pyrroles; Structure-Activity Relationship | 2007 |
Design and synthesis of hepatoselective, pyrrole-based HMG-CoA reductase inhibitors.
Topics: Animals; Cricetinae; Dose-Response Relationship, Drug; Drug Design; Fluorobenzenes; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver; Models, Molecular; Molecular Structure; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Structure-Activity Relationship; Sulfonamides | 2007 |
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
Topics: Animals; Antioxidants; Atherosclerosis; Benzoxazines; Cholesterol, LDL; Farnesyl-Diphosphate Farnesyltransferase; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Mice; Rats; Thiazines | 2011 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Lipoproteins, LDL; Male; Mice; Oxidative Stress; Probucol; Rats | 2013 |
Antihyperlipidemic morpholine derivatives with antioxidant activity: An investigation of the aromatic substitution.
Topics: Animals; Antioxidants; Binding Sites; Catalytic Domain; Disease Models, Animal; Farnesyl-Diphosphate Farnesyltransferase; Hyperlipidemias; Hypolipidemic Agents; Inhibitory Concentration 50; Microsomes, Liver; Molecular Docking Simulation; Morpholines; Rats | 2015 |
Relationship between genetic polymorphism of drug transporters and the efficacy of Rosuvastatin, atorvastatin and simvastatin in patients with hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Polymorphism, Genetic; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2021 |
Anti-Obesity Effects of Aqueous Extracts of Sunbanghwalmyung-Eum in High-Fat- and High-Cholesterol-Diet-Induced Obese C57BL/6J Mice.
Topics: Adipogenesis; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; CCAAT-Enhancer-Binding Protein-alpha; Cholesterol; Diet, High-Fat; Hyperlipidemias; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Plant Extracts; PPAR gamma; Simvastatin; Water | 2022 |
Establishment of a lipid metabolism disorder model in ApoEb mutant zebrafish.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Ezetimibe; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Mammals; Simvastatin; Zebrafish | 2022 |
Interaction pattern and
Topics: Administration, Oral; Animals; Chitosan; Cholesterol, Dietary; Delayed-Action Preparations; Disease Models, Animal; Drug Administration Schedule; Drug Carriers; Drug Compounding; Drug Liberation; Female; Humans; Hyperlipidemias; Mice; Molecular Docking Simulation; Nanoparticles; Particle Size; Proton Magnetic Resonance Spectroscopy; Simvastatin; Spectroscopy, Fourier Transform Infrared | 2019 |
[Effects of changing the appearance of medications in safety and adherence in chronic patients over 65 years of age in primary care. CAMBIMED Study].
Topics: Aged; Aged, 80 and over; Amlodipine; Antihypertensive Agents; Chronic Disease; Drug Labeling; Drug Packaging; Enalapril; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Longitudinal Studies; Male; Medication Adherence; Medication Errors; Primary Health Care; Prospective Studies; Simvastatin | 2020 |
Down syndrome, severe psoriasis, and increased risk for cardiovascular events.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Down Syndrome; Fatal Outcome; Female; Heart Septal Defects; Humans; Hyperlipidemias; Hypolipidemic Agents; Interferon-gamma; Metoprolol; Middle Aged; Myocardial Infarction; Polycythemia; Psoriasis; Risk Factors; Severity of Illness Index; Simvastatin; Triamcinolone Acetonide | 2019 |
The protective effects of Salvia officinalis essential oil compared to simvastatin against hyperlipidemia, liver, and kidney injuries in mice submitted to a high-fat diet.
Topics: Animals; Diet, High-Fat; Hyperlipidemias; Kidney; Liver; Mice; Oils, Volatile; Salvia officinalis; Simvastatin | 2020 |
Molecular characterization of gut microbiota in high‑lipid diet‑induced hyperlipidemic rats treated with simvastatin.
Topics: Animals; Diet; Feces; Gastrointestinal Microbiome; Hyperlipidemias; Male; Metabolic Networks and Pathways; Rats; Rats, Sprague-Dawley; RNA, Ribosomal, 16S; Simvastatin | 2020 |
Effect of Phoenix dactylifera seeds (dates) extract in triton WR-1339 and high fat diet induced hyperlipidaemia in rats: A comparison with simvastatin.
Topics: Animals; Antioxidants; Biomarkers; Diet, High-Fat; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Male; Obesity; Phoeniceae; Plant Extracts; Polyethylene Glycols; Polyphenols; Rats, Wistar; Seeds; Simvastatin; Solvents; Weight Gain | 2020 |
PHOSPHO1 Gene DNA Methylations are Associated with a Change in HDL-C Response to Simvastatin Treatment.
Topics: Cholesterol, HDL; DNA Methylation; Humans; Hyperlipidemias; Phosphoric Monoester Hydrolases; Simvastatin; Triglycerides | 2020 |
Chronopharmacology of simvastatin on hyperlipidaemia in high-fat diet-fed obese mice.
Topics: Animals; Chronopharmacokinetics; Circadian Clocks; Circadian Rhythm Signaling Peptides and Proteins; Diet, High-Fat; Drug Chronotherapy; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Liver; Male; Mice; Mice, Obese; Random Allocation; RNA, Messenger; Simvastatin | 2020 |
Effect of
Topics: Adult; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 1; Cholesterol, HDL; DNA Methylation; Female; Humans; Hyperlipidemias; Lipids; Male; Middle Aged; Simvastatin; Treatment Outcome | 2021 |
Excessive expression of miR-1a by statin causes skeletal injury through targeting mitogen-activated protein kinase kinase kinase 1.
Topics: Animals; Apoptosis; Cells, Cultured; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; MAP Kinase Kinase Kinase 1; Mice; Mice, Knockout, ApoE; MicroRNAs; Muscle Fibers, Skeletal; Muscular Diseases; Physical Conditioning, Animal; Primary Cell Culture; RNA, Small Interfering; Simvastatin; Up-Regulation | 2021 |
Therapeutic advancement of simvastatin-loaded solid lipid nanoparticles (SV-SLNs) in treatment of hyperlipidemia and attenuating hepatotoxicity, myopathy and apoptosis: Comprehensive study.
Topics: Animals; Apoptosis; Biological Availability; Chemical and Drug Induced Liver Injury; Drug Carriers; Drug Delivery Systems; Hyperlipidemias; Lipids; Male; Muscular Diseases; Nanoparticles; Particle Size; Rats; Rats, Wistar; Simvastatin | 2021 |
Hypolipidemic and reduced nitrergic effects of p-hydroxycinnamic diesters extracted from Copernicia prunifera in mice challenged by a high-fat diet.
Topics: Administration, Oral; Animals; Arecaceae; Biomarkers; Body Weight; Coumaric Acids; Diet, High-Fat; Disease Models, Animal; Female; Hyperlipidemias; Hypolipidemic Agents; Inflammation; Interleukin-1beta; Lipid Metabolism; Lipids; Liver; Liver X Receptors; Male; Mice, Inbred C57BL; Plant Extracts; Simvastatin | 2021 |
Ternary Eutectic Ezetimibe-Simvastatin-Fenofibrate System and the Physical Stability of Its Amorphous Form.
Topics: Anticholesteremic Agents; Chemistry, Pharmaceutical; Drug Combinations; Drug Compounding; Drug Stability; Drug Storage; Ezetimibe; Fenofibrate; Humans; Hyperlipidemias; Simvastatin | 2021 |
The Anti-hyperlipidemia Effects of Raw Polygonum multiflorum Extract in Vivo.
Topics: Acetyl-CoA Carboxylase; Administration, Oral; Animals; Chemical and Drug Induced Liver Injury; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Drugs, Chinese Herbal; Fallopia multiflora; Fatty Acid Synthase, Type I; Hepatocytes; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Medicine, Chinese Traditional; Rats, Sprague-Dawley; Simvastatin; Triglycerides | 2017 |
Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
Topics: Adolescent; Age Factors; Child; Dose-Response Relationship, Drug; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Polymorphism, Genetic; Simvastatin; Young Adult | 2018 |
Association of ABCC2 polymorphism and gender with high-density lipoprotein cholesterol response to simvastatin.
Topics: Asian People; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Polymorphism, Single Nucleotide; Prospective Studies; Simvastatin; Triglycerides | 2018 |
Hypolipidemic effect of Fragarianilgerrensis Schlecht. medicine compound on hyperlipidemic rats.
Topics: Animals; Antioxidants; Centella; Cholesterol, HDL; Disease Models, Animal; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Lipids; Liver; Plant Extracts; Rats; Simvastatin; Triglycerides; Triterpenes | 2018 |
Simvastatin therapy in adolescent mice attenuates HFD-induced depression-like behavior by reducing hippocampal neuroinflammation.
Topics: Animals; Behavior, Animal; Brain; Depression; Diet, High-Fat; Hippocampus; Hyperlipidemias; Inflammation; Male; Mice; Mice, Inbred C57BL; Neurons; Neuroprotective Agents; Obesity; Serotonin; Simvastatin | 2019 |
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Topics: Adult; Atherosclerosis; Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Female; Gastric Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Postoperative Period; Preoperative Period; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Tandem Mass Spectrometry | 2019 |
Effect of statins on hearing function and subjective tinnitus in hyperlipidemic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Audiometry; Female; Hearing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Tinnitus; Young Adult | 2019 |
Fixed Dose Combination Formulations: Multilayered Platforms Designed for the Management of Cardiovascular Disease.
Topics: Aspirin; Cardiovascular Diseases; Dosage Forms; Drug Combinations; Drug Compounding; Drug Delivery Systems; Drug Design; Drug Liberation; Hot Melt Extrusion Technology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Polyethylene Glycols; Polyvinyls; Pyrrolidines; Simvastatin; Solubility; Vinyl Compounds | 2019 |
Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model.
Topics: Administration, Oral; Animals; Crystallization; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Nanoparticles; Particle Size; Rats; Rats, Sprague-Dawley; Simvastatin | 2019 |
Effects of simvastatin and fenofibrate on butyrylcholinesterase activity in the brain, plasma, and liver of normolipidemic and hyperlipidemic rats.
Topics: Animals; Anticholesteremic Agents; Brain; Butyrylcholinesterase; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Liver; Plasma; Rats; Rats, Wistar; Simvastatin | 2019 |
Lipotoxicity-associated inflammation is prevented by guarana (
Topics: Adenosine; Adenosine Triphosphate; Animals; Anti-Inflammatory Agents; Caffeine; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperlipidemias; Inflammation; Lymphocytes; Male; Rats; Rats, Wistar; Simvastatin; Theobromine; Theophylline | 2021 |
Budget impact of rosuvastatin initiation in high-risk hyperlipidemic patients from a US managed care perspective.
Topics: Adult; Atorvastatin; Costs and Cost Analysis; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Managed Care Programs; Models, Economic; Myocardial Infarction; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Stroke; Sulfonamides; United States | 2013 |
Cardiovascular event rates in atorvastatin patients versus patients switching from atorvastatin to simvastatin.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular System; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Longitudinal Studies; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk; Simvastatin; Treatment Outcome; Young Adult | 2013 |
Effect of simvastatin on plasma homocysteine levels and its modification by MTHFR C677T polymorphism in Chinese patients with primary hyperlipidemia.
Topics: Administration, Oral; Adult; Asian People; Biomarkers; Chi-Square Distribution; China; Chromatography, High Pressure Liquid; Down-Regulation; Female; Homocysteine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Linear Models; Male; Methylenetetrahydrofolate Reductase (NADPH2); Middle Aged; Multivariate Analysis; Polymerase Chain Reaction; Polymorphism, Genetic; Simvastatin; Time Factors; Treatment Outcome | 2013 |
Characterization of statin dose response in electronic medical records.
Topics: Algorithms; Alleles; Atorvastatin; Cholesterol, LDL; Cohort Studies; Databases, Factual; Dose-Response Relationship, Drug; Electronic Health Records; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2014 |
Statin therapy correlated CYP2D6 gene polymorphism and hyperlipidemia.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP2D6; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Polymorphism, Genetic; Simvastatin | 2014 |
An 85-year-old with muscle pain.
Topics: Aged, 80 and over; Drug Substitution; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Myalgia; Simvastatin; Withholding Treatment | 2014 |
Association of simvastatin and hyperlipidemia with periodontal status and bone metabolism markers.
Topics: Adult; Aged; Alcohol Drinking; Biomarkers; Blood Sedimentation; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Collagen Type I; Cross-Sectional Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Osteocalcin; Osteoprotegerin; Peptide Fragments; Peptides; Periodontal Attachment Loss; Periodontal Index; Procollagen; Simvastatin; Smoking; Triglycerides | 2014 |
Systemic inflammation in patients with inflammatory joint diseases does not influence statin dose needed to obtain LDL cholesterol goal in cardiovascular prevention.
Topics: Aged; Arthritis, Psoriatic; Arthritis, Rheumatoid; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Comorbidity; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Rosuvastatin Calcium; Simvastatin; Spondylitis, Ankylosing | 2015 |
Evaluation of antihyperlipidemic potency of a polyherbomineral formulation (AF-LIP) in experimental animal models.
Topics: Acyl Coenzyme A; Animals; Atherosclerosis; Cholesterol; Diet, High-Fat; Dose-Response Relationship, Drug; Feces; Female; Fenofibrate; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Male; Plant Extracts; Polyethylene Glycols; Rats; Rats, Wistar; Simvastatin | 2014 |
Anti-hypercholesterolemic effect of Pistacia lentiscus fatty oil in egg yolk-fed rabbits: a comparative study with simvastatin.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet; Egg Yolk; Female; Fruit; Hyperlipidemias; Lipids; Phytotherapy; Pistacia; Plant Oils; Rabbits; Simvastatin; Triglycerides | 2014 |
Antiatherosclerotic Potential of Rhizoma Polygonati Polysaccharide in Hyperlipidemia-induced Atherosclerotic Hamsters.
Topics: Animals; Aorta; Apolipoproteins; Atherosclerosis; Cricetinae; Diet, Atherogenic; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Hyperlipidemias; Lipids; Male; Polygonatum; Polysaccharides; Simvastatin | 2015 |
Metabolomic analysis of simvastatin and fenofibrate intervention in high-lipid diet-induced hyperlipidemia rats.
Topics: 3-Hydroxybutyric Acid; Animals; Biomarkers; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatinine; Diet, High-Fat; Fenofibrate; Hyperlipidemias; Isoleucine; Linoleic Acid; Male; Metabolome; Metabolomics; Ornithine; Rats; Rats, Sprague-Dawley; Simvastatin; Tyrosine | 2014 |
Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
Topics: Atorvastatin; Dose-Response Relationship, Drug; Drug Costs; Drugs, Generic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Practice Patterns, Physicians'; Rosuvastatin Calcium; Simvastatin; South Africa | 2015 |
Diabetes and hyperlipidemia induce dysfunction of VSMCs: contribution of the metabolic inflammation/miRNA pathway.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Connexins; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Nephropathies; Drug Therapy, Combination; Female; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; MicroRNAs; Muscle, Smooth, Vascular; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Renal Artery; rho-Associated Kinases; Simvastatin; Vasculitis | 2015 |
Downregulation of miR-146a, cyclooxygenase-2 and advanced glycation end-products in simvastatin-treated older patients with hyperlipidemia.
Topics: Aged; Cyclooxygenase 2; Down-Regulation; Gene Expression Regulation; Glycation End Products, Advanced; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; MicroRNAs; Simvastatin | 2016 |
Comparative evaluation of Nigella sativa (Kalonji) and simvastatin for the treatment of hyperlipidemia and in the induction of hepatotoxicity.
Topics: Alanine Transaminase; Animals; Chemical and Drug Induced Liver Injury; Cholesterol; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Nigella sativa; Phytotherapy; Rats; Rats, Sprague-Dawley; Simvastatin; Triglycerides | 2015 |
Synthesis and antihyperlipidemic activity of piperic acid derivatives.
Topics: Animals; Fatty Acids, Unsaturated; Hyperlipidemias; Hypolipidemic Agents; Molecular Structure; Rats; Simvastatin | 2015 |
Effects of Cydonia oblonga Miller leaf and fruit flavonoids on blood lipids and anti-oxydant potential in hyperlipidemia rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Cholesterol; Flavonoids; Fruit; Glutathione Peroxidase; Hyperlipidemias; Lipids; Liver; Male; Malondialdehyde; Phytotherapy; Plant Extracts; Plant Leaves; Rats; Rosaceae; Simvastatin; Superoxide Dismutase | 2015 |
Metabolic and structural bone disturbances induced by hyperlipidic diet in mice treated with simvastatin.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Diet, High-Fat; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Mice; Mice, Inbred C57BL; Simvastatin | 2015 |
Regulation effect of Aspirin Eugenol Ester on blood lipids in Wistar rats with hyperlipidemia.
Topics: Animals; Aspirin; Dietary Fats; Eugenol; Hyperlipidemias; Hypolipidemic Agents; Male; Random Allocation; Rats; Simvastatin | 2015 |
Application of Response Surface Methodology for Design and Optimization of Reservoir-type Transdermal Patch of Simvastatin.
Topics: Administration, Cutaneous; Animals; Biomarkers; Cyclohexenes; Disease Models, Animal; Drug Compounding; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Limonene; Lipids; Male; Middle Aged; Models, Statistical; Permeability; Poloxamer; Rats, Sprague-Dawley; Simvastatin; Skin; Skin Absorption; Technology, Pharmaceutical; Terpenes; Time Factors; Transdermal Patch | 2016 |
Formulation optimization and characterization of transdermal film of simvastatin by response surface methodology.
Topics: Acrylic Resins; Administration, Cutaneous; Animals; Drug Carriers; Drug Compounding; Hyperlipidemias; Male; Microscopy, Electron, Scanning; Polyvinyl Alcohol; Rats; Rats, Sprague-Dawley; Simvastatin; Skin; Skin Absorption; Tensile Strength | 2016 |
Lipid-lowering treatment patterns in patients with new cardiovascular events - estimates from population-based register data in Sweden.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk Factors; Simvastatin; Sweden | 2016 |
[Drug interaction in 63-year-old male sportsman--a case report].
Topics: Amlodipine; Confusion; Dizziness; Drug Interactions; Exercise; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Myalgia; Simvastatin | 2015 |
Effects of LEP G2548A and LEPR Q223R Polymorphisms on Serum Lipids and Response to Simvastatin Treatment in Chinese Patients With Primary Hyperlipidemia.
Topics: Anticholesteremic Agents; Asian People; Female; Genetic Predisposition to Disease; Humans; Hyperlipidemias; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, Leptin; Simvastatin | 2017 |
Antioxidant and Hypolipidemic Activity of the Hydroethanolic Extract of Curatella americana L. Leaves.
Topics: Animals; Antioxidants; Diet, Carbohydrate Loading; Dilleniaceae; Erythrocytes; Hemolysis; Hyperlipidemias; Hypolipidemic Agents; Lipid Peroxidation; Lipids; Malondialdehyde; Plant Extracts; Plant Leaves; Rats; Rats, Wistar; Simvastatin | 2016 |
Simvastatin-loaded nanostructured lipid carriers attenuate the atherogenic risk of erythrocytes in hyperlipidemic rats.
Topics: Animals; Atherosclerosis; Drug Carriers; Drug Liberation; Erythrocytes; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney; Lipid Metabolism; Lipids; Liver; Nanostructures; Rats; Risk; Simvastatin | 2017 |
Comparative effects of piperine and simvastatin in fat accumulation and antioxidative status in high fat-induced hyperlipidemic rats.
Topics: Adipose Tissue; Alkaloids; Animals; Antioxidants; Benzodioxoles; Diet, High-Fat; Dietary Fats; Fatty Liver; Hyperlipidemias; Male; Oxidative Stress; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Sprague-Dawley; Simvastatin | 2016 |
Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity.
Topics: Acidosis; Adult; Animals; Cell Line; Chylomicron Remnants; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Male; Mice; Models, Biological; Muscular Diseases; Pravastatin; Simvastatin | 2017 |
Do different tendons exhibit the same response following chronic exposure to statins?
Topics: Animals; Atorvastatin; Collagen Type I; Enzyme Precursors; Extracellular Matrix; Gelatinases; Glycosaminoglycans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxyproline; Hyperlipidemias; Male; Rats; Rats, Wistar; Simvastatin; Tendon Injuries; Tendons | 2017 |
Neuroprotective effects of pretreatment with quercetin as assessed by acetylcholinesterase assay and behavioral testing in poloxamer-407 induced hyperlipidemic rats.
Topics: Acetylcholinesterase; Animals; Behavior, Animal; Blood Glucose; Brain; Hyperlipidemias; Lipids; Male; Maze Learning; Neuroprotective Agents; Poloxamer; Quercetin; Rats, Wistar; Simvastatin | 2017 |
NICE on lipid modification: NICE's simplified approach to lipids will not work.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2008 |
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients.
Topics: Aged; Anticholesteremic Agents; Bezafibrate; Cholestenones; Cholesterol; Cholesterol 7-alpha-Hydroxylase; Cholestyramine Resin; Complement C4; Data Interpretation, Statistical; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Kinetics; Male; Middle Aged; Reference Standards; Simvastatin | 2008 |
NICE on lipid modification: NICE's simplified approach can't not work.
Topics: Cholesterol, LDL; Dose-Response Relationship, Drug; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2008 |
[Effects of HuDan Granules on lipid metabolism and antioxidant activity of mice with hyperlipidemia].
Topics: Animals; Antioxidants; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Lipid Peroxidation; Male; Mice; Phytotherapy; Random Allocation; Simvastatin; Superoxide Dismutase; Triglycerides | 2008 |
Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin.
Topics: Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Atenolol; Azetidines; Carcinoma, Non-Small-Cell Lung; Coronary Artery Disease; Drug Interactions; Erlotinib Hydrochloride; Ezetimibe; Female; Humans; Hyperlipidemias; Hypertension; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis; Simvastatin; Tomography, X-Ray Computed | 2008 |
Lipid lowering activity of Citri unshii pericarpium in hyperlipemic rats.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Citrus; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Plant Extracts; Plant Structures; Rats; Rats, Sprague-Dawley; Simvastatin; Triglycerides | 2008 |
Pravastatin, a 3-hydroxy-3-methyl-glutharyl coenzyme A inhibitor does not show pleiotropic effects in patients with systemic lupus erythematosus.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lupus Erythematosus, Systemic; Severity of Illness Index; Simvastatin; Tumor Necrosis Factor-alpha | 2009 |
[Simvastatin therapy and effect on hiperlipidemia and vascular status in nephrotic children with sustained dyslipidemia].
Topics: Adolescent; Carotid Arteries; Child; Female; Femoral Artery; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Nephrosis; Simvastatin; Treatment Outcome; Ultrasonography | 2009 |
[Treatment of blood lipids abnormality in patients with diabetes mellitus].
Topics: Cholesterol, LDL; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Triglycerides | 2009 |
Letter by Tershakovec et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Risk Factors; Simvastatin; Vasculitis | 2009 |
Letter by Westerink and Visseren regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
Letter by Settergren et al regarding article, "Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation".
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Endothelium, Vascular; Ezetimibe; Humans; Hyperlipidemias; rho-Associated Kinases; Simvastatin; Vasculitis | 2009 |
Effects of simvastatin on plasma lipoproteins and hearing loss in apolipoprotein E gene-deficient mice.
Topics: Animals; Anticholesteremic Agents; Apolipoproteins E; Atherosclerosis; Female; Hair Cells, Auditory; Hearing Loss, Sensorineural; Hyperlipidemias; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Severity of Illness Index; Simvastatin | 2009 |
Microvascular Reactivity and Endothelial Function in Type 2 Diabetic Patients with Hyperlipidemia Treated with Simvastatin: 3-year Follow-up.
Topics: Cell Adhesion Molecules; Diabetes Mellitus, Type 2; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Laser-Doppler Flowmetry; Lipids; Male; Microcirculation; Middle Aged; Simvastatin; Skin; Vasodilation | 2009 |
[Effects of simvastatin on vasa vasorum and aortic endothelial function in rats].
Topics: Animals; Aorta; Arteriosclerosis; Endothelium, Vascular; Hyperlipidemias; Hypolipidemic Agents; Male; Nitric Oxide; Random Allocation; Rats; Rats, Sprague-Dawley; Simvastatin; Vasa Vasorum; Vascular Endothelial Growth Factor A | 2010 |
Combined hyperlipidemia in patients with lysinuric protein intolerance.
Topics: Adolescent; Adult; Amino Acid Metabolism, Inborn Errors; Atorvastatin; Biomarkers; Child; Child, Preschool; Cholesterol; Cholesterol, HDL; Cystatin C; Disease Progression; Female; Finland; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Retrospective Studies; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Triglycerides; Young Adult | 2010 |
LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
Topics: Adult; Aged; Atorvastatin; Case-Control Studies; Cholesterol, LDL; Cohort Studies; Databases, Factual; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Multivariate Analysis; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin | 2010 |
Primed polymorphonuclear leukocytes constitute a possible link between inflammation and oxidative stress in hyperlipidemic patients: effect of statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Neutrophils; Oxidative Stress; Simvastatin | 2010 |
The utility of observational studies in clinical decision making: lessons learned from statin trials.
Topics: Atorvastatin; Cardiovascular Diseases; Comparative Effectiveness Research; Decision Making; Epidemiologic Studies; Evidence-Based Medicine; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Observation; Pyrroles; Simvastatin | 2010 |
Anti-obesity and antihyperlipidaemic effect of Hunteria umbellata seed extract in experimental hyperlipidaemia.
Topics: Administration, Oral; Animals; Anti-Obesity Agents; Apocynaceae; Cardiovascular Diseases; Disease Models, Animal; Dose-Response Relationship, Drug; Feeding Behavior; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Liver; Male; Olive Oil; Plant Extracts; Plant Oils; Polyethylene Glycols; Rats; Rats, Wistar; Seeds; Simvastatin; Time Factors; Weight Gain | 2010 |
Early outcome of acute ischemic stroke in hyperlipidemic patients under atorvastatin versus simvastatin.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Brain Ischemia; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hyperlipidemias; Lipids; Male; Medical Records; Middle Aged; Neuroprotective Agents; Pyrroles; Retrospective Studies; Severity of Illness Index; Simvastatin; Statistics as Topic; Stroke; Stroke Rehabilitation; Treatment Outcome | 2010 |
Rhabdomyolysis in a patient receiving ranolazine and simvastatin.
Topics: Acetanilides; Angina Pectoris; Creatine Kinase; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Piperazines; Ranolazine; Rhabdomyolysis; Simvastatin | 2010 |
Anti-hyperlipidemic and cardioprotective effects of Ocimum sanctum L. fixed oil in rats fed a high fat diet.
Topics: Animals; Cardiotonic Agents; Cholesterol; Creatine Kinase, MB Form; Dietary Fats; Hyperlipidemias; Hypolipidemic Agents; L-Lactate Dehydrogenase; Liver Function Tests; Male; Ocimum; Phytotherapy; Plant Leaves; Plant Oils; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2010 |
Efficacy and safety of ezetimibe and low-dose simvastatin as primary treatment for dyslipidemia in peritoneal dialysis patients.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol; Cholesterol, LDL; Drug Combinations; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 2010 |
A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia.
Topics: Adult; Aspirin; Cholesterol, LDL; Computer Simulation; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Models, Biological; Predictive Value of Tests; Simvastatin; Young Adult | 2011 |
Beneficial effects of cordycepin on metabolic profiles of liver and plasma from hyperlipidemic hamsters.
Topics: Animals; Cholesterol; Cricetinae; Deoxyadenosines; Disease Models, Animal; Hyperlipidemias; Liver; Male; Metabolome; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Simvastatin; Triglycerides | 2011 |
Effects of simvastatin on apolipoprotein M in vivo and in vitro.
Topics: Animals; Apolipoproteins; Apolipoproteins M; Dietary Fats; Gene Expression; Hep G2 Cells; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Mice; Simvastatin | 2011 |
Half-dose ezetimibe add-on to statin therapy is effective in improving resistant hyperlipidaemia in Asian patients with ischaemic heart disease.
Topics: Aged; Asia; Azetidines; Cholesterol; Cohort Studies; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins, LDL; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Simvastatin; Treatment Outcome | 2011 |
Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; United States | 2011 |
Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Apolipoprotein B-100; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reference Values; Regression Analysis; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides; Young Adult | 2011 |
Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Drug Substitution; Drugs, Generic; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Medication Adherence; Simvastatin; Triglycerides | 2011 |
Lipid lowering effect of Cinnamomum zeylanicum in hyperlipidaemic albino rabbits.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cinnamomum zeylanicum; Diet, High-Fat; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Hyperlipidemias; Lipids; Phytotherapy; Plant Bark; Plant Extracts; Powders; Rabbits; Simvastatin; Triglycerides | 2012 |
Antihyperlipidaemic effects of Eugenia jambolana fruit in diet induced hyperlipidaemic rats.
Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Diet; Drug Therapy, Combination; Ethanol; Fruit; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Phytotherapy; Plant Extracts; Rats; Rats, Sprague-Dawley; Simvastatin; Syzygium; Time Factors; Triglycerides | 2011 |
PTU induction provide quick screening of hypo and hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Antithyroid Agents; Azetidines; Cholesterol; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Propylthiouracil; Rats; Simvastatin | 2011 |
Comparison of simvastatin with Eugenia Jambolana fruit pulp in their effects on alanine transferase, aspartate aminotransferase and creatinine phosphokinase levels of hyperlipidaemic rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Creatine Kinase; Fruit; Hyperlipidemias; Male; Phytotherapy; Plant Extracts; Random Allocation; Rats; Rats, Wistar; Simvastatin; Syzygium; Treatment Outcome | 2011 |
[Statin-ezetimibe combination in hyperlipidemia treatment].
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Male; Middle Aged; Pyrroles; Simvastatin | 2012 |
Intronic variants in SLCO1B1 related to statin-induced myopathy are associated with the low-density lipoprotein cholesterol response to statins in Chinese patients with hyperlipidaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Asian People; Cholesterol, LDL; Female; Fluorobenzenes; Genetic Variation; Humans; Hyperlipidemias; Introns; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Clinical consequences following regulatory changes in respect to reimbursement of statins cost by the Icelandic Social Insurance Administration.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hyperlipidemias; Iceland; Male; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Reimbursement Mechanisms; Rosuvastatin Calcium; Simvastatin; Social Security; Sulfonamides; Treatment Outcome | 2012 |
[Experience with simvastatin therapy for the achievement of osteoprotective effects in women with hyperlipidemia].
Topics: Absorptiometry, Photon; Biological Availability; Biomarkers; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Collagen; Diet, Fat-Restricted; Drug Monitoring; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Middle Aged; Osteocalcin; Peptide Fragments; Protective Agents; Simvastatin; Treatment Outcome | 2012 |
Genes and cardiovascular risk.
Topics: Anticholesteremic Agents; Apolipoproteins B; Cardiovascular Diseases; Cholesterol, LDL; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Male; Polymorphism, Single Nucleotide; Simvastatin | 2013 |
Lack of association between SLCO1B1 polymorphism and the lipid-lowering effects of atorvastatin and simvastatin in Chinese individuals.
Topics: Adult; Aged; Analysis of Variance; Asian People; Atorvastatin; Biomarkers; Chi-Square Distribution; China; Cholesterol, HDL; Cholesterol, LDL; Cytochrome P-450 CYP3A; Female; Gene Frequency; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pharmacogenetics; Phenotype; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyrroles; Simvastatin; Treatment Outcome; Triglycerides | 2013 |
Doctor, my dentist wants your opinion.
Topics: Angioplasty; Antibiotic Prophylaxis; Aspirin; Dental Care for Chronically Ill; Dentists; Drug Interactions; Endocarditis; Humans; Hyperlipidemias; Macrolides; Male; Mitral Valve Prolapse; Myocardial Ischemia; Platelet Aggregation Inhibitors; Simvastatin; Streptococcal Infections; Tooth Extraction; Viridans Streptococci | 2013 |
Rhabdomyolysis with simvastatin and nefazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Piperazines; Rhabdomyolysis; Simvastatin; Triazoles | 2002 |
[Simvastatin and extrinsic coagulation pathway in peritoneally dialyzed patients].
Topics: Adult; Aged; Blood Coagulation Factors; Factor VII; Factor Xa; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Failure, Chronic; Lipoproteins; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Platelet Aggregation; Simvastatin; Statistics, Nonparametric; Time Factors; von Willebrand Factor | 2002 |
Simvastatin-associated rhabdomyolysis demonstrated on bone scan.
Topics: Abdomen; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Muscle, Skeletal; Pelvis; Radionuclide Imaging; Radiopharmaceuticals; Rhabdomyolysis; Shoulder; Simvastatin; Technetium Tc 99m Medronate; Thigh; Whole-Body Counting | 2002 |
Endothelial cell response to hyperlipemia. Activation-dysfunction-injury, the protective role of simvastatin.
Topics: Animals; Aorta, Abdominal; Cricetinae; Dietary Fats; Endothelium, Vascular; Hyperlipidemias; Male; Simvastatin | 2002 |
[Statin is indicated to all patients with high risk of complications of coronary heart disease irrespective of the level of low density lipoprotein cholesterol. Results of HPS].
Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Randomized Controlled Trials as Topic; Simvastatin | 2002 |
Chronic actinic dermatitis secondary to simvastatin.
Topics: Chronic Disease; Diagnosis, Differential; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Neck; Photosensitivity Disorders; Simvastatin | 2002 |
In the statin era, how important are intense lifestyle changes?
Topics: Coronary Disease; Diet, Fat-Restricted; Exercise; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Risk Factors; Simvastatin | 2003 |
C-reactive protein and lipids may respond differently to statins.
Topics: C-Reactive Protein; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2003 |
Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis.
Topics: Biomarkers; Cholesterol; Endothelium, Vascular; Humans; Hyperlipidemias; Hypolipidemic Agents; Intercellular Adhesion Molecule-1; Lipoproteins, LDL; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin; Thrombomodulin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2002 |
Transfusion medicine illustrated: an unusual plasmapheresis product.
Topics: Adult; Glomerulosclerosis, Focal Segmental; Humans; Hyperlipidemias; Male; Nephrosis, Lipoid; Nephrotic Syndrome; Plasma Exchange; Simvastatin | 2003 |
[Bilateral occipital intraparenchymatous hemorrhage].
Topics: Cerebral Hemorrhage; Functional Laterality; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Male; Middle Aged; Occipital Lobe; Simvastatin; Tomography, X-Ray Computed | 2003 |
Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease.
Topics: Anticholesteremic Agents; Antineoplastic Agents; Apolipoproteins; Biomarkers; C-Reactive Protein; Coronary Disease; Female; Fibrinogen; Hemostatics; Humans; Hyperlipidemias; Lipoproteins; Male; Matrix Metalloproteinase 9; Middle Aged; Placebo Effect; Protease Inhibitors; Simvastatin; Thromboplastin; Thrombosis; Tissue Inhibitor of Metalloproteinase-1; Tumor Necrosis Factor-alpha | 2003 |
Variable influence of statins on isoprostanes in hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Dinoprost; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Isoprostanes; Lovastatin; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Smoking | 2003 |
Reduced expression of endothelial connexin37 and connexin40 in hyperlipidemic mice: recovery of connexin37 after 7-day simvastatin treatment.
Topics: Animals; Aorta; Connexins; Down-Regulation; Endothelium, Vascular; Female; Gap Junction alpha-4 Protein; Gap Junction alpha-5 Protein; Gap Junctions; Hyperlipidemias; Male; Mice; Mice, Inbred C57BL; Microscopy, Immunoelectron; Simvastatin; Tissue Distribution | 2003 |
Effect of statin therapy on total mortality. Trial in a more varied population.
Topics: Antioxidants; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Mortality; Placebos; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin; Treatment Outcome | 2003 |
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hypertension; Male; Middle Aged; Niacin; Obesity; Risk Factors; Simvastatin | 2003 |
The influence of apolipoprotein B and E gene polymorphisms on the response to simvastatin therapy in patients with hyperlipidemia.
Topics: Aged; Alleles; Apolipoproteins B; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Female; Gene Frequency; Humans; Hyperlipidemias; Male; Middle Aged; Mutation; Polymorphism, Restriction Fragment Length; Simvastatin; Triglycerides | 2003 |
[Comparative study of lipid lowering effect and influence on platelet aggregation of atorvastatin and simvastatin in patients ischemic heart disease with type II diabetes and combined hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Heptanoic Acids; Humans; Hyperlipidemias; Male; Middle Aged; Myocardial Ischemia; Platelet Aggregation; Pyrroles; Simvastatin | 2003 |
Atrial fibrillation induced by simvastatin treatment in a 61-year-old man.
Topics: Atrial Fibrillation; Electrocardiography; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2003 |
[Primary prevention of stroke. What helps--what does not help? The guidelines of the German Society of Neurology briefly summarized].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Alcohol Drinking; Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Arrhythmias, Cardiac; Aspirin; Atenolol; Atrial Fibrillation; Carotid Artery, Internal; Carotid Stenosis; Chlorthalidone; Clinical Trials as Topic; Diabetes Complications; Diuretics; Doxazosin; Female; Fibrinolytic Agents; Hormone Replacement Therapy; Humans; Hyperlipidemias; Hypertension; Hypolipidemic Agents; Life Style; Losartan; Male; Neurology; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Pravastatin; Primary Prevention; Risk Factors; Simvastatin; Smoking; Societies, Medical; Stroke | 2003 |
Simvastatin-induced rhabdomyolysis in a CsA-treated renal transplant recipient.
Topics: Adult; Cyclosporine; Drug Interactions; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Kidney Transplantation; Rhabdomyolysis; Simvastatin | 2003 |
Rhabdomyolysis associated with simvastatin-nefazodone therapy.
Topics: Antidepressive Agents, Second-Generation; Depressive Disorder; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Piperazines; Rhabdomyolysis; Simvastatin; Triazoles | 2003 |
Histopathology and regression of retinal hard exudates in diabetic retinopathy after reduction of elevated serum lipid levels.
Topics: Adult; Apolipoproteins B; Cholesterol Esters; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Diet Therapy; Exercise Therapy; Exudates and Transudates; Fatal Outcome; Fluorescein Angiography; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunoenzyme Techniques; Laser Coagulation; Lipids; Male; Middle Aged; Plasmapheresis; Retinal Vessels; Simvastatin | 2003 |
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Niacin; Particle Size; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin | 2003 |
Statins lower plasma and lymphocyte ubiquinol/ubiquinone without affecting other antioxidants and PUFA.
Topics: Antioxidants; Atorvastatin; Catalase; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coenzymes; Erythrocytes; Fatty Acids, Unsaturated; Glutathione; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lymphocytes; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Ubiquinone; Vitamin E | 2003 |
A case of severe hyperlipidemia caused by long-term tube feedings.
Topics: Aged; Carnitine; Dietary Sucrose; Enteral Nutrition; Female; Food, Formulated; Humans; Hyperlipidemias; Hypolipidemic Agents; Rhabdomyolysis; Simvastatin | 2003 |
Effects of HR780, a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in Watanabe heritable hyperlipidemic rabbits and cholesterol-fed rabbits.
Topics: Animals; Animals, Genetically Modified; Bile; Cholesterol; Cholesterol, Dietary; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Japan; Lipids; Liver; Male; Pyridines; Rabbits; Simvastatin | 2004 |
Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Simvastatin; Treatment Outcome; Triglycerides | 2004 |
Rhabdomyolysis and compartment syndrome with coadministration of risperidone and simvastatin.
Topics: Acute Disease; Adult; Antipsychotic Agents; Compartment Syndromes; Drug Interactions; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Rhabdomyolysis; Risperidone; Schizophrenia; Simvastatin | 2004 |
[Rhabdomyolysis secondary to the interaction of statins with macrolides in a renal transplant patient].
Topics: Aged; Anticholesteremic Agents; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Hyperlipidemias; Inactivation, Metabolic; Kidney Transplantation; Male; Postoperative Complications; Respiratory Tract Infections; Rhabdomyolysis; Simvastatin | 2004 |
Rhabdomyolysis resulting from interaction of simvastatin and clarithromycin demonstrated by Tc-99m MDP scintigraphy.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Interactions; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Radionuclide Imaging; Radiopharmaceuticals; Respiratory Tract Infections; Rhabdomyolysis; Simvastatin; Technetium Tc 99m Medronate | 2004 |
Statin-associated exacerbation of myasthenia gravis.
Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone | 2004 |
A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan.
Topics: Area Under Curve; Atorvastatin; Biomedical Research; Databases, Bibliographic; Drug Interactions; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Japan; Pharmacology, Clinical; Pravastatin; Product Labeling; Pyrroles; Quinolines; Simvastatin; United States; United States Food and Drug Administration | 2005 |
[How sure is the combined lipid lowering?].
Topics: Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin | 2005 |
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Studies; Cyclosporine; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Male; Niacin; Oxidoreductases, N-Demethylating; Physicians; Pravastatin; Prevalence; Product Surveillance, Postmarketing; Pyrroles; Simvastatin; Time Factors | 2005 |
Simvastatin, fenofibrate, and rhabdomyolysis.
Topics: Aged; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Rhabdomyolysis; Simvastatin | 2005 |
Anti-oxidative effect of fluvastatin in hyperlipidemic type 2 diabetic patients.
Topics: Aged; Antioxidants; Cholestenes; Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Erythrocyte Membrane; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Indoles; Male; Middle Aged; Oxidative Stress; Pravastatin; Prospective Studies; Simvastatin; Thiobarbituric Acid Reactive Substances | 2005 |
Colonoscopic features of simvastatin-induced colitis suggest ischemia as an etiologic mechanism.
Topics: Aged; Biopsy; Colitis; Colon, Descending; Colon, Transverse; Colonoscopy; Diagnosis, Differential; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Ischemia; Male; Simvastatin | 2005 |
Simvastatin inhibits NOR-1 expression induced by hyperlipemia by interfering with CREB activation.
Topics: Animals; Arteries; Cells, Cultured; Cholesterol, LDL; Coronary Vessels; Cyclic AMP Response Element-Binding Protein; DNA-Binding Proteins; Humans; Hyperlipidemias; Hypolipidemic Agents; Models, Animal; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Nerve Tissue Proteins; Receptors, Steroid; Receptors, Thyroid Hormone; rhoA GTP-Binding Protein; Simvastatin; Swine | 2005 |
Rhabdomyolysis after concomitant use of cyclosporine and simvastatin in a patient transplanted for multiple myeloma.
Topics: Cyclosporine; Humans; Hyperlipidemias; Hypolipidemic Agents; Immunosuppressive Agents; Male; Middle Aged; Multiple Myeloma; Rhabdomyolysis; Simvastatin; Stem Cell Transplantation | 2005 |
Effect of statin therapy on serum trace element status in dyslipidaemic subjects.
Topics: Adult; Antioxidants; Atorvastatin; Blood Chemical Analysis; Ceruloplasmin; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Inflammation; Lipids; Male; Middle Aged; Pyrroles; Simvastatin; Trace Elements | 2005 |
[A case of drug-induced pneumonia possibly associated with simvastatin].
Topics: Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lung Diseases, Interstitial; Middle Aged; Radiography, Thoracic; Simvastatin; Tomography, X-Ray Computed | 2005 |
MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apolipoproteins E; Atherosclerosis; Atorvastatin; Cellulose, Oxidized; Diet; Disease Models, Animal; Endothelium, Vascular; Heptanoic Acids; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins; Male; Mice; Mice, Knockout; Pyrroles; Simvastatin; Triglycerides; Vascular Cell Adhesion Molecule-1 | 2006 |
Hypolipemic effect of water extracts of Picrorrhiza rhizoma in PX-407 induced hyperlipemic ICR mouse model with hepatoprotective effects: a prevention study.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Body Weight; Cholesterol; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Mice; Mice, Inbred ICR; Organ Size; Phytotherapy; Picrorhiza; Plant Extracts; Simvastatin; Triglycerides | 2006 |
Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia.
Topics: Aged; Anticholesteremic Agents; Antioxidants; Cholesterol, LDL; Female; Glutathione Peroxidase; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Oxidation-Reduction; Simvastatin | 2006 |
The expression of monocyte chemoattractant protein-1 and C-C chemokine receptor 2 in post-kidney transplant patients and the influence of simvastatin treatment.
Topics: Adult; Chemokine CCL2; Female; Gene Expression; Humans; Hyperlipidemias; Kidney Transplantation; Leukocytes, Mononuclear; Lipids; Male; Receptors, CCR2; Receptors, Chemokine; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Simvastatin | 2006 |
Influence of HMG-CoA-reductase inhibitors on the body fat status.
Topics: Adipose Tissue; Aged; Arterial Occlusive Diseases; Atorvastatin; Body Composition; Body Mass Index; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Simvastatin | 2006 |
Autoimmune hepatitis triggered by statins.
Topics: Atorvastatin; Female; Hepatitis, Autoimmune; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Pyrroles; Simvastatin | 2006 |
[Interaction of cyclosporin with CSE inhibitors].
Topics: Cyclosporine; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Rhabdomyolysis; Simvastatin | 2006 |
Simvastatin down regulates mRNA expression of RANTES and CCR5 in posttransplant renal recipients with hyperlipidemia.
Topics: Adult; Chemokine CCL5; Female; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Kidney Failure, Chronic; Kidney Transplantation; Lipids; Male; Middle Aged; Postoperative Complications; Receptors, CCR5; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Simvastatin | 2006 |
Reproducible tendinitis-like symptoms related to statin therapy.
Topics: Adult; Aged; Gemfibrozil; Humans; Hyperlipidemias; Male; Simvastatin; Tendinopathy | 2006 |
Strong suppression of high-sensitivity C-reactive protein level and its mediated pro-atherosclerotic effects with simvastatin: in vivo and in vitro studies.
Topics: Analysis of Variance; Atherosclerosis; Blotting, Western; C-Reactive Protein; Case-Control Studies; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; In Vitro Techniques; Intercellular Adhesion Molecule-1; Male; Middle Aged; Risk Factors; Simvastatin; Umbilical Veins; Vascular Cell Adhesion Molecule-1 | 2007 |
Apolipoprotein E genotype affects the response to lipid-lowering therapy in Chinese patients with type 2 diabetes mellitus.
Topics: Apolipoproteins E; Cholesterol; Diabetes Mellitus, Type 2; Gene Frequency; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lovastatin; Simvastatin; Treatment Outcome | 2007 |
Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.
Topics: Ananas; Animals; Blood Glucose; Cholesterol; Dietary Fats; Dose-Response Relationship, Drug; Enzyme Activation; Ethanol; Fenofibrate; Fructose; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoprotein Lipase; Male; Mice; Mice, Inbred ICR; Plant Extracts; Plant Leaves; Simvastatin; Triglycerides | 2007 |
Effects of Tribuli saponins on ventricular remodeling after myocardial infarction in hyperlipidemic rats.
Topics: Animals; Cardiac Volume; Cholesterol; Disease Models, Animal; Dose-Response Relationship, Drug; Heart Ventricles; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Myocardial Infarction; Plant Extracts; Random Allocation; Rats; Rats, Sprague-Dawley; Saponins; Simvastatin; Stroke Volume; Tribulus; Ultrasonography; Ventricular Remodeling | 2007 |
Case reports: alopecia universalis: hair growth following initiation of simvastatin and ezetimibe therapy.
Topics: Alopecia Areata; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Hair; Humans; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2007 |
Dry adsorbed emulsion of simvastatin: optimization and in vivo advantage.
Topics: Acrylates; Adsorption; Animals; Anticholesteremic Agents; Biological Availability; Calorimetry, Differential Scanning; Cholesterol; Emulsions; Female; Glycerol; Hyperlipidemias; Lipoproteins, HDL; Microscopy, Electron, Scanning; Particle Size; Polysorbates; Powders; Rats; Rats, Sprague-Dawley; Rheology; Silicon Dioxide; Simvastatin; Solubility; Soybean Oil; Viscosity; X-Ray Diffraction | 2007 |
The cost-effectiveness of the treatment of high risk women with osteoporosis, hypertension and hyperlipidaemia in Sweden.
Topics: Aged; Aged, 80 and over; Alendronate; Antihypertensive Agents; Bone Density Conservation Agents; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Simvastatin; Sweden | 2008 |
[Clinico-diagnostic significance of cytokine activation and changes of morphofunctional parameters of the heart in patients with chronic heart failure and possibilities of correction of revealed disturbances with simvastatin].
Topics: Chronic Disease; Cytokines; Female; Heart Failure; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2007 |
HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia.
Topics: Aged; Apolipoprotein A-I; Cholesterol; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Gene Expression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin | 2008 |
[Quantitative ultrasonic integrated backscatter of the intima-media complex, serum level of matrix metalloprotease-9 and simvastatin in hyperlipemia patients].
Topics: Adult; Anticholesteremic Agents; Carotid Arteries; Female; Humans; Hyperlipidemias; Male; Matrix Metalloproteinase 9; Middle Aged; Simvastatin; Tunica Intima; Tunica Media; Ultrasonography | 2008 |
Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients.
Topics: Adult; Arrhythmias, Cardiac; Cardiac Electrophysiology; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Prospective Studies; Simvastatin; Time Factors | 2008 |
Management of patients with dyslipidaemia.
Topics: Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Cohort Studies; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Randomized Controlled Trials as Topic; Risk; Scandinavian and Nordic Countries; Simvastatin | 1995 |
Depression-induced absenteeism in relation to antihyperlipidemic treatment: a study using GAZEL cohort data.
Topics: Absenteeism; Adult; Cohort Studies; Depression; Diet, Fat-Restricted; Female; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Prevalence; Risk Factors; Simvastatin; Surveys and Questionnaires | 1995 |
Implications of 4S evidence on baseline lipid levels.
Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Myocardial Infarction; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 1995 |
Descriptive study of lipid-modulating drug use in a French professional population.
Topics: Adult; Cross-Sectional Studies; Female; Follow-Up Studies; France; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Occupations; Pharmacoepidemiology; Simvastatin; Thyroid Diseases | 1994 |
Hyperlipidemia in renal transplant recipients: does it matter and can we treat it?
Topics: Adult; Female; Graft Occlusion, Vascular; Humans; Hyperlipidemias; Kidney Transplantation; Lovastatin; Male; Middle Aged; Myocardial Ischemia; Prospective Studies; Simvastatin | 1995 |
Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Pravastatin; Simvastatin | 1994 |
Efficacy of low-density-lipoprotein lowering with statins.
Topics: Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1994 |
Hyperlipidemia in renal transplant recipients: natural history and response to treatment.
Topics: Adolescent; Adult; Aged; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Kidney Transplantation; Lovastatin; Male; Middle Aged; Simvastatin; Time Factors; Triglycerides | 1994 |
Aberrant hypothalamic-pituitary-ovarian axis in the Watanabe heritable hyperlipidemic rabbit.
Topics: Animals; Cholesterol; Estradiol; Female; Fertility; Follicle Stimulating Hormone; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypothalamo-Hypophyseal System; Lovastatin; Luteinizing Hormone; Male; Ovary; Progesterone; Rabbits; Receptors, LDL; Simvastatin; Sperm-Ovum Interactions | 1994 |
Cholesterol-lowering intervention and coronary artery disease after cardiac transplantation.
Topics: Adult; Anticholesteremic Agents; Cholesterol, Dietary; Cholesterol, LDL; Coronary Disease; Female; Heart Transplantation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Simvastatin; Survival Analysis | 1994 |
Dislipemia in patients undergoing continuous ambulatory peritoneal dialysis: pharmacological therapy (simvastatin) versus hemodialysis.
Topics: Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Peritoneal Dialysis, Continuous Ambulatory; Renal Dialysis; Retrospective Studies; Simvastatin; Uremia | 1993 |
The effect of simvastatin on dyslipemia in continuous ambulatory peritoneal dialysis patients.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Simvastatin | 1993 |
Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.
Topics: Adolescent; Child; Child, Preschool; Cholesterol; Combined Modality Therapy; Creatinine; Diet; Drug Resistance; Enzyme Inhibitors; Feeding Behavior; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Infant; Lovastatin; Male; Nephrotic Syndrome; Retrospective Studies; Serum Albumin; Simvastatin; Triglycerides | 1996 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Coronary Disease; Diet; Factor VII; Humans; Hyperlipidemias; Lovastatin; Risk Factors; Simvastatin; Smoking | 1995 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Sweden | 1996 |
The effect of simvastatin on HDL cholesterol in hyperlipidemic patients. Evidence of a relationship with the changes in serum triglyceride level.
Topics: Adult; Aged; Analysis of Variance; Apoproteins; Cholesterol, HDL; Diet, Fat-Restricted; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Cost-benefit analysis of lipid lowering therapy.
Topics: Cost-Benefit Analysis; Drug Monitoring; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin; Survival Rate | 1997 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin | 1997 |
Hyperlipidaemia and cardiovascular disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Myocardial Ischemia; Risk Factors; Simvastatin | 1997 |
Lipid-lowering with statins and fibrinolytic parameters.
Topics: Cholesterol, LDL; Fibrinolysis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Simvastatin | 1997 |
Increased incidence of myositis in patients treated with high-dose simvastatin.
Topics: Animals; Cells, Cultured; Cholesterol, LDL; Creatine Kinase; GTP-Binding Proteins; Heart; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Incidence; Myocardium; Myositis; Rats; Simvastatin | 1998 |
Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse.
Topics: Adenosine; Aged; Coronary Circulation; Coronary Vessels; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; Simvastatin; Vasodilation | 1998 |
[Is combined statin and fibrate therapy indicated in the management of mixed hyperlipidemia?].
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Simvastatin | 1998 |
Cheilitis due to treatment with simvastatin.
Topics: Adult; Cheilitis; Facial Dermatoses; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 1998 |
Detecting and correcting hyperlipidemia.
Topics: Algorithms; Decision Trees; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Postmenopause; Simvastatin | 1998 |
Coronary artery disease: the Scandinavian Simvastatin Survival Study experience.
Topics: Angina Pectoris; Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hyperlipidemias; Male; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Randomized Controlled Trials as Topic; Scandinavian and Nordic Countries; Simvastatin | 1998 |
[Dyslipidemia in diabetes mellitus: statins treatment raises survival of patients].
Topics: Diabetes Complications; Diabetes Mellitus; Follow-Up Studies; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Retrospective Studies; Simvastatin; Survival Rate | 1999 |
Simvastatin decreases aldehyde production derived from lipoprotein oxidation.
Topics: Aldehydes; Antioxidants; Humans; Hyperlipidemias; Hypolipidemic Agents; In Vitro Techniques; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Simvastatin; Vitamin E | 1999 |
Statins and C-reactive protein.
Topics: C-Reactive Protein; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1999 |
Effects of statins in thrombosis and aortic lesion development in a dyslipemic rabbit model.
Topics: Animals; Aorta; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Male; Platelet Adhesiveness; Platelet Aggregation; Pyrroles; Rabbits; Simvastatin; Thrombosis | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Lipid-lowering therapy corrects endothelial cell dysfunction in a short time but does not affect hypercoagulable state even after long-term use in hyperlipidemic patients.
Topics: Blood Coagulation; Endothelium, Vascular; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Simvastatin; Time Factors | 1999 |
Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs.
Topics: Animals; Apolipoproteins B; Cholesterol; Chromatography, High Pressure Liquid; Disease Models, Animal; Electrophoresis, Polyacrylamide Gel; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins, VLDL; Liver; Male; Quinolines; Receptors, LDL; Simvastatin; Sterols; Triglycerides | 1999 |
HMG CoA reductase inhibitors and cardiac surgery.
Topics: Coronary Artery Bypass; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Platelet Aggregation; Postoperative Complications; Preoperative Care; Simvastatin; Thrombocytosis; Treatment Outcome | 1999 |
Plasma levels of E-selectin in normolipemic and hyperlipemic arteriopathic patients after vasoactive and lipid-lowering treatment.
Topics: Arterial Occlusive Diseases; Bezafibrate; E-Selectin; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Vasoconstrictor Agents | 2000 |
[Type 2 diabetic patients. Aggressive management of increased blood lipids].
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hyperlipidemias; Hypolipidemic Agents; Simvastatin; Survival Rate | 2000 |
Cost-effectiveness of treating hyperlipidemia in the presence of diabetes : who should be treated?
Topics: Adult; Aged; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Female; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Life Expectancy; Male; Middle Aged; Models, Theoretical; Personnel Selection; Simvastatin | 2000 |
Conversion of patients from simvastatin to lovastatin in an outpatient pharmacy clinic.
Topics: Aged; Ambulatory Care; Blood Glucose; Dose-Response Relationship, Drug; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Liver; Lovastatin; Male; New Mexico; Pharmacy Service, Hospital; Prospective Studies; Simvastatin | 2000 |
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease?
Topics: Adult; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Drug Costs; Female; Health Care Costs; Humans; Hyperlipidemias; Male; Middle Aged; Primary Prevention; Risk Factors; Simvastatin | 2001 |
Making the most of cholesterol-lowering margarines.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Coronary Disease; Costs and Cost Analysis; Female; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Margarine; Phytosterols; Randomized Controlled Trials as Topic; Simvastatin; Sitosterols; Time Factors | 2001 |
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? A response to Grover et al.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Morbidity; Quality of Life; Quality-Adjusted Life Years; Simvastatin | 2001 |
Normocholesterolaemic dyslipidaemia: is there a role for fibrates?
Topics: Algorithms; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Decision Trees; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Patient Selection; Simvastatin; Treatment Outcome; Triglycerides | 2001 |
Electron-beam tomography coronary calcium scores are superior to Framingham risk variables for predicting the measured proximal stenosis burden.
Topics: Body Burden; Calcinosis; Coronary Angiography; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Predictive Value of Tests; Regression Analysis; Risk Factors; Simvastatin; Tomography, X-Ray Computed | 2001 |
Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia.
Topics: Adult; Anticholesteremic Agents; Cardiolipins; Cholesterol; Cholesterol, HDL; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Lysophosphatidylcholines; Male; Middle Aged; Phosphatidylcholines; Phosphatidylethanolamines; Phospholipids; Simvastatin; Sphingomyelins; Triglycerides | 2001 |
Hyperlipidaemia and cardiovascular disease.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Endothelium, Vascular; Humans; Hyperlipidemias; Lovastatin; Nitric Oxide; Pravastatin; Rabbits; Simvastatin | 2001 |
Effect of pravastatin-to-simvastatin conversion on low-density-lipoprotein cholesterol.
Topics: Aged; Anticholesteremic Agents; Chi-Square Distribution; Cholesterol, LDL; Coronary Disease; Drug Administration Schedule; Female; Hospitals, Veterans; Humans; Hyperlipidemias; Male; Middle Aged; Pharmacy Service, Hospital; Pravastatin; Prospective Studies; Risk Factors; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2001 |
Managed care trends in statin usage.
Topics: Anticholesteremic Agents; Atorvastatin; Databases, Factual; Drug Costs; Drug Utilization Review; Fatty Acids, Monounsaturated; Fluvastatin; Health Care Sector; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Indoles; Lovastatin; Managed Care Programs; Pravastatin; Pyridines; Pyrroles; Simvastatin; United States | 2001 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
Pancreatitis associated with simvastatin plus fenofibrate.
Topics: Aged; Drug Therapy, Combination; Fatal Outcome; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Pancreatitis, Acute Necrotizing; Simvastatin | 2002 |
Adrenocorticotrophic hormone exerts marked lipid-lowering effects in simvastatin-treated patients.
Topics: Adrenocorticotropic Hormone; Aged; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Simvastatin; Statistics, Nonparametric; Treatment Outcome | 2001 |
The use of simvastatin in analbuminaemia.
Topics: Adult; Creatine Kinase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Serum Albumin; Simvastatin; South Africa | 2001 |
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Niacin; Pravastatin; Risk Factors; Simvastatin; Stroke; Treatment Outcome | 2002 |
Immunosuppressive effects of statins.
Topics: Adjuvants, Immunologic; Cells, Cultured; Histocompatibility Antigens Class II; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Interferon-gamma; Lovastatin; Pravastatin; Simvastatin; Tumor Cells, Cultured | 2002 |
The effect of simvastatin on diabetic dyslipidemia.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipidemias; Male; Middle Aged; Prognosis; Prospective Studies; Simvastatin; Treatment Outcome | 2002 |
Simvastatin reduces neointimal thickening in low-density lipoprotein receptor-deficient mice after experimental angioplasty without changing plasma lipids.
Topics: Angioplasty; Animals; Anti-Inflammatory Agents; Apoptosis; Carotid Stenosis; Cell Division; Cell Movement; Graft Occlusion, Vascular; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leukocytes; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Receptors, LDL; Simvastatin | 2002 |
[Dyslipidemia in the uremic patient: the therapeutic role played by simvastatin].
Topics: Aged; Anticholesteremic Agents; Combined Modality Therapy; Drug Evaluation; Female; Humans; Hyperlipidemias; Hypertriglyceridemia; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Renal Dialysis; Simvastatin; Uremia | 1992 |
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Management of non-nephrotic hyperlipidaemia of chronic renal failure with simvastatin.
Topics: Female; Humans; Hyperlipidemias; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Pilot Projects; Simvastatin | 1991 |
Simvastatin in the media.
Topics: Advertising; Anticholesteremic Agents; Humans; Hyperlipidemias; Lovastatin; Simvastatin | 1989 |
[Effect of a long-term treatment with simvastatin, an inhibitor of HMG-CoA reductase, in dyslipidemic patients at high risk].
Topics: Aged; Cardiovascular Diseases; Drug Evaluation; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Risk; Simvastatin | 1989 |
Cholesterol synthesis inhibitors in hyperlipidaemia.
Topics: Anticholesteremic Agents; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type III; Lovastatin; Male; Middle Aged; Simvastatin | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |